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Network meta-analysis (NMA) extends pairwise meta-analysis by synthesizing both 
direct evidence within trials and indirect evidence across trials. NMA can address a 
broader research question than pairwise meta-analysis by comparing all interventions for 
a given condition in a single analysis. However, identifying, collecting, appraising, and 
synthesizing all relevant evidence is resource-intensive and time-consuming. 
Bibliographic databases such as PubMed, Embase and The Cochrane Register of 
Controlled Trials (CENTRAL) are almost always searched to identify trial reports. For 
regulated products (e.g., pharmaceuticals and biologics), approval packages available 
from the U.S. Food and Drug Administration (FDA) website (Drugs@FDA) contain 
information about trials that supported the marketing approval. ClinicalTrials.gov is 
another data source that can be tapped to identify trial reports.  
Objective 
To test a rapid NMA approach using Drugs@FDA and ClinicalTrials.gov to identify 
trials of drug interventions; to compare the usefulness of these two data sources to that of 
bibliographic databases; and to assess how results might be affected by using different 
data sources.  
Methods 
Building upon a recent NMA and available data sets, we searched ClinicalTrials.gov for 
randomized controlled trials on first-line medications for glaucoma. Two individuals 
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independently selected trials and extracted data. When a trial was identified in multiple 
sources, we compared trial reports from different data sources. We fit random effects 
NMA models to analyze trial reports from different data sources for intraocular pressure 
(IOP) at 3 months, the outcome of interest. We compared the findings from these 
analyses. 
Results 
We identified 115 trial reports from bibliographic databases, 28 from Drugs@FDA, and 
27 from ClincalTrials.gov. These 170 trial reports described 139 unique trials including 
29,158 participants. Only 78% (121/139) of the unique trials provided sufficient data for 
NMAs. When a trial was associated with multiple reports from different sources, 
information provided were inconsistent across the three sources in PICOT (patient, 
intervention, comparator, outcome, and time point), statistical methods, and results. 
ClinicalTrials.gov provided less trial information compared to Drugs@FDA and 
bibliographic databases. The effect estimates generally agreed when different sources of 
data were used for NMA, although the precision varied.  
Conclusions 
A rapid NMA approach using Drugs@FDA to identify trials of drug interventions is 
feasible. In our case example, NMA based on trial reports from Drugs@FDA alone 
provided reasonably precise estimates of relative effects. Reporting of trial design and 
results can be improved in both the drug approval packages and on ClinicalTrials.gov.    
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Systematic review is comprehensive but slow in production. 
A systematic review uses systematic methods to identify, collect, appraise, and synthesize 
the body of evidence to address a clearly defined research question.1 Conclusions drawn 
from systematic review can inform healthcare practice, public policy, insurance coverage, 
and future research.2 Meta-analysis, an optional component of systematic review, uses 
statistical methods to combine results from individual studies.3  
 
Although being regarded as a cornerstone of evidence-based practice, systematic reviews 
are not produced fast enough to meet decision-making needs.4-8 It takes between 6 
months to 2 years to conduct a systematic review, with the median time from final search 
to publication being 15 months.5,9,10 A large proportion of time is devoted to identifying 
relevant studies from searching multiple data sources, which are not available from a 
single library or website.11 Collecting all relevant evidence requires a comprehensive 
search of multiple databases and sources to identify eligible studies.1,12-14 Public data 
sources for systematic reviews include journal articles, conference abstracts, trial 
registrations, regulatory information, whereas clinical study reports (CSRs) and 
individual patient data are less accessible to the public.11  
 
Systematic reviewers search a median number of four databases, screen 5,000 or more 
citations, typically, 10% of which are considered relevant and are reviewed in full text, 
and 1% are ultimately included in a systematic review.15-17 With the fast-evolving 
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technology and emerging public health problems, there are increasing demands for access 
to up-to-date research evidence. The considerable time and resource requirements for 
systematic review production may not be conducive for the decision-making paradigm.  
 
Compared to traditional pairwise meta-analysis, network meta-analysis (NMA) 
facilitates multiple treatment comparisons but it usually requires a broader evidence 
base. 
As a quantitative component of systematic reviews, pairwise meta-analysis addresses the 
question of the relative effects of two interventions by combining (as a weighted average) 
the results of multiple studies that have assessed the two interventions.18,19 When 
properly conducted, pair-wise meta-analysis can improve the precision of estimates, 
explore heterogeneity and inconsistencies among individual studies, and inform future 
research questions.1 
 
However, there are usually more than two interventions available for a given condition. 
Doctors and patients are sometimes offered a bewildering number of treatment options. 
Taking first-line medical treatment for open angle glaucoma as an example, patients can 
choose from more than ten different types of eye drops approved by the U.S. Food and 
Drug Administration (FDA) from four different classes.20-22 Traditional pairwise meta-
analysis cannot address the question “which treatment works best?” In some cases, 
different pairwise meta-analyses produced contradictory results, precluding a coherent 
picture of the comparative effectiveness of all treatments.23-25  
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The ever-increasing treatment options in clinical practice create urgent needs for 
sophisticated evidence synthesis methods that go beyond pairwise comparisons. NMA, an 
extension of pairwise meta-analysis, can address a broader research question than 
pairwise meta-analysis by comparing all interventions for a given condition in a single 
analysis.26 As indicated by its name, NMA aims to build a network where nodes represent 
interventions while the edges represent direct comparisons between two interventions.26-
28 NMA facilitates indirect comparisons of interventions that have not been studied in a 
head-to-head manner.29 If two interventions A and B have one intermediate comparator 
C, A and B can be compared indirectly providing indirect evidence. In cases where 
studies that directly compared treatments A and B also exist, combining direct and 
indirect evidence (as a weighted average) can increase the precision in effect estimates.29-
31 NMAs can therefore accomplish the task of “all-way” comparisons. 
 
Two types of findings are produced by NMA: relative effect estimates of any two 
interventions in the network and ranking probabilities of all interventions.32,33 
Conclusions on the comparative effectiveness of all interventions in a network can be 
drawn based on both the estimates of relative effects and ranking probabilities.  
 
Given that NMA is highly informative for decision-making by providing relative effects 
of multiple interventions, it has been used increasingly in the assessment of health 
technologies, especially pharmacological interventions.33-35 The improved capability 
gained in NMA is not without cost. Compared to pairwise meta-analysis, NMA requires a 
broader scope of search to include all relevant interventions and studies.35 
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Rapid approach with limited search is appealing for systematic review. 
Rapid reviews, defined as reviews that use methods to accelerate traditional systematic 
review process, have been introduced to provide timely information for decision making 
in recent years.9,35 When Hartling and colleagues surveyed users of systematic reviews 
(guideline developers, healthcare providers, research funders, and health insurers), they 
found that limiting the literature search by database, journal, year is among the most 
acceptable trade-offs to increase efficiency.36 Rapid reviews are deemed necessary when 
timeliness is crucial, and especially when a traditional systematic review is unavailable. 
For example, Medicare faces increasing pressure to conduct health technology 
assessments within less than 2 months.37 More recently, Canadian Agency for Drugs and 
Technologies in Health offers “Rapid Response Service” to healthcare providers and 
other decision makers that are tailored to their urgent/time-sensitive inquiries.38,39 
Cochrane Rapid Review Methods Group was established in 2015 to develop rapid review 
methodology in the hope that reviews are produced quickly without sacrificing scientific 
rigor.40 
 
Shortcuts in literature search may pose a threat to validity of the review findings, a 
concern that can only be addressed by empirical research.9,36,41 Some researchers have 
found that searching data sources in addition to MEDLINE generated small incremental 
gain.14,42 Furthermore, almost all the empirical research has been conducted in the context 
of systematic reviews using pairwise meta-analysis but not NMA. We describe known 
issues around data sources for pairwise meta-analysis below and will outline knowledge 
gaps for NMA. 
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Regulatory information and trial registration complements published literatures for 
systematic reviews. 
Regulatory information and trial registration can provide data unavailable from published 
literature about trials included in systematic reviews.12,43 For drugs approved by FDA, the 
approval packages available from Drugs@FDA 
(https://www.fda.gov/Drugs/InformationOnDrugs/ucm135821.htm) contain summaries of 
trials submitted to the agency for marketing approval. They are available on the agency’s 
website for drugs approved since 1997; for drugs approved before 1997, information 
must be requested through a freedom of information request 
(https://www.accessdata.fda.gov/scripts/foi/FOIRequest/requestinfo.cfm).44 Similar 
regulatory documents are available at Health Canada Products Database and European 
Medicines Agency’s European Public Assessment Reports.45,46 
  
ClinicalTrials.gov, run by the United States National Library of Medicine (NLM) of the 
National Institutes of Health (NIH), is one of the largest clinical trials registries 
worldwide. ClinicalTrials.gov was established in 2000 in response to the trial registration 
requirement of the 1997 Food and Drug Administration Modernization Act (FDAMA 
1997) (and therefore trials conducted before 2000 may not be identifiable from 
ClinicalTrials.gov).47,48 It was expanded in 2008 to include a database for registering 
summary results under 2007 Food and Drug Administration Amendment Act (FDAAA 
2007). 49,50 The 2016 “final rule” issued by Department of Health and Human Services 
and complementary “final policy” issued by NIH further expanded regulatory mandates 
for trial registration and results submission. The final rule and final policy require that 
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clinical trials (except phase I and early device trials) of FDA-regulated drugs, biologics, 
and devices, and clinical trials funded in whole or in part by the NIH be registered and 
have summary results information posted as of January 18, 2017.51-54 As of April 03, 
2018, ClinicalTrials.gov has included registrations for more than 270,000 studies from 
203 countries and summary results for more than 30,000 studies.55 There are also other 
trial registries available, such as WHO International Clinical Trials Registry Platform 
(ICTRP)56 and EU Clinical Trial Register (EU CTR).57 
 
For pairwise meta-analysis, the value of data from FDA approval packages and 
ClinicalTrials.gov has been demonstrated in many empirical studies.58-62 Above all, FDA 
approval packages and ClinicalTrials.gov serve as valuable sources for identifying 
unpublished trials.60,63 Previous studies also have examined completeness and accuracy 
of information presented in published literature with information provided in the FDA 
approval packages or ClinicalTrials.gov, as a way to examine selective reporting. In 
general, data reported in published literature showed a greater treatment effect overall 
than data presented in non-published data sources.43,58,64,65 Selective reporting impacts the 
results and inferences in systematic reviews and meta-analyses.65,66 
 
Knowledge gaps for NMA 
In the context of NMA, we have identified two empirical studies that examined the 
usefulness of data from FDA approval packages and ClinicalTrials.gov. Trinquart and 
colleagues examined the impact of reporting bias in NMA using 74 trials identified from 
FDA approval packages and their 51 matching publications.67 Trials identified from the 
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FDA approval packages were considered as the reference and internally “valid”. After 
conducting a series of NMAs, the authors found that when trial results were partially or 
inaccurately reported in journal articles, the effect sizes would be overestimated, and the 
relative rankings of drugs would differ when using these two different data sources. 67 
This study builds the case that FDA approval packages are an important source for 
identifying trial reports for drug interventions, and perhaps provide more valid data than 
their matching publications. 
 
Cameron and colleagues conducted a rapid NMA on the effectiveness of antithrombotic 
medications for atrial fibrillation, where the authors analyzed data derived solely from 
ClinicalTrials.gov and compared findings with those based on data retrieved from The 
Cochrane Library, MEDINE, and Embase, the traditional approach.68 Compared to the 
traditional approach, the rapid approach identified 6/12 trial reports (78,444/82,396 
participants) covering 8/11 available interventions; trials missed were those published 
before the launch of ClinialTrials.gov results database in 2008.68 The authors argued that 
clinical conclusions based on the rapid approach were similar to those based on 
traditional approach where all trials were identified, however, the rapid approach only 
took a few weeks, a fraction of time and resources compared to the traditional approach.68 
 
These two examples suggest that NMA may be less sensitive to partial retrieval of all 
available data and that the choice of data source matters. Either omitting or focusing on 




In this study, we aim to address the following questions: Is it worth looking for trial data 
from Drugs@FDA and ClinicalTrials.gov for NMAs of drug interventions? How 
different would the results be by using different data sources (i.e., Drugs@FDA or 
ClinicalTrials.gov compared to traditional bibliographic databases) in NMAs? To 
expedite the production of NMA, is it sufficient to only include trial data from 
Drugs@FDA or ClinialTrials.gov for NMA of drug interventions?  
 
Objectives 
To test a rapid NMA approach using Drugs@FDA and ClinicalTrials.gov to identify 
trials of drug interventions; to compare the usefulness of these two data sources to that of 
bibliographic databases; and to assess how results might be affected by using different 







We built upon a recent NMA and available dataset on the comparative effectiveness of 
first-line medications for open angle glaucoma conducted by our group.22 Table 1 
summarizes the status of dataset that was made available for this thesis research. In brief, 
the underlying NMA has already identified and extracted data from trials published in the 
bibliographic databases, including the Cochrane Register of Controlled Trials 
(CENTRAL) in The Cochrane Library, MEDLINE, and Embase. The search was run in 
March 2014 without any date or language restriction. A search of the Drugs@FDA was 




We used the same eligibility criteria as the previous NMA.22 Trials were eligible for our 
NMA if they meet all of the following criteria: (1) they were randomized controlled trials 
(RCT) with parallel design; (2) 60% or more participants had a diagnosis of primary open 
angle glaucoma or ocular hypertension; (3) they evaluated first-line topical medications 
in reducing intraocular pressure (IOP) or progression of visual field damage; (4) they 
compared a single active treatment with no treatment/placebo or another single active 
treatment.22   
 
Trials were excluded if: (1) they enrolled less than 10 participants in each group; (2) they 
evaluated combination medications (generally prescribed after treatment failure of single 
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first-line medication); or (3) participants were followed for an outcome for less than 28 
days after randomization.22   
 
The primary outcome for the systematic review and NMA is mean IOP at 3 months in 
millimeters of mercury (mmHg). If more than one IOP measures were available, we used 
the following priority order in data extraction: mean diurnal IOP (the average of IOP 
values measured during daytime), 24-hour mean IOP, peak IOP value, morning IOP, and 
trough IOP value. When the 3-month IOP measure was not available, we used the IOP 
measured at a follow-up time point closest to 3 months.  
 
Identifying trials from ClinicalTrials.gov 
Working in collaboration with a trained information specialist (Lori Rosman), we 
searched ClinicalTrials.gov using a combination of generic drug names, brand names, 
and synonyms in December 2016 (search strategy available in Appendix 1). We 
downloaded search results from ClinicalTrials.gov as comma-separated values and 
imported them into a database for de-duplication and assessment of eligibility.  
 
Trial selection 
Two individuals independently assessed the trial registration records identified by the 
searches for potential eligibility. Discrepancies were resolved through discussion with a 
third person. 
 
Data extraction and risk of bias assessment 
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Two individuals independently extracted data from each included trial. We extracted data 
items on study design, PICOT (patient population, intervention, comparison, outcome, 
and time points), risk of bias, and quantitative results for IOP using existing electronic 
forms developed by our group in the Systematic Review Data Repository 
(http://srdr.ahrq.gov).69,70  
 
We used the Cochrane Risk of Bias Tool to assess the risk of bias in the following 
domains: randomization sequence generation, allocation concealment, masking of 
participants, and masking of IOP assessors.1 We also documented the funding source(s) 
for each trial. Discrepancies were resolved through discussion with a third person.  
 
Mapping trials identified from different data sources 
In this thesis, we will use bibliographic database, Drugs@FDA, and ClinicalTrials.gov to 
describe data sources; and will use journal articles, approval packages, and trial 
registrations to refer to the types of records available from each data source.  
 
A trial may be identifiable from more than one data source. For example, a trial published 
in a journal article (and identified from searching bibliographic databases) may also be 
identifiable from Drugs@FDA or Clinicaltrials.gov. We matched trials identified from 
Drugs@FDA and ClinicalTrials.gov to trials identified from bibliographic databases. We 
also matched trials between Drugs@FDA and ClinicalTrials.gov. We used trial 
publication link and trial registration number on Clinicaltrials.gov, the sponsor, the 
intervention and comparator, the description of trial design and results for matching.  
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When a trial was identified from more than one data source, we compared the 
completeness and consistency of information including trial design, the intervention and 
comparator, baseline characteristics, outcomes (including the primary and secondary 
outcomes of the trial), and results.   
 
Qualitative synthesis  
We evaluated the characteristics of included trials by data sources to examine the 
usefulness of the three data sources. We compared characteristics such as the year of 
trials and the sample size, the regions where the participants were recruited, the eligibility 
criteria, the follow-up time, and the type of analysis used.  
 
Quantitative synthesis 
In all analyses, we combined different concentrations of the same medication. Our effect 
estimate is the mean difference in IOP at 3 months for each pair of treatment comparison. 
In RCTs, the baseline mean IOP is expected to be balanced among treatment groups. 
Therefore, difference in mean change from baseline between two groups estimates the 
same underlying relative effect as mean difference between two groups using only the 
follow-up values.1 We thus combined mean reduction in IOP at 3 months with mean IOP 
at 3 months in our analysis.  
 
We analyzed five networks of trials: (1) all unique trials identified from three data 
sources; (2) trials identified from bibliographic databases alone; (3) trials identified from 
Drugs@FDA alone; (4) trials identified from ClinicalTrials.gov alone; (5) trials identified 
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from bibliographic databases but not found on Drugs@FDA or ClinicalTrials.gov. For 
all-unique trial network, when data were available from more than one source, we chose 
data source using the following order of priority: Drugs@FDA, bibliographic databases, 
ClinicalTrials.gov. For other trial networks, we used data from the corresponding data 
source. 
 
For each network, we first conducted pairwise meta-analyses for every direct comparison 
using a DerSimonian and Laird random-effects model,71 implemented in STATA 
package ‘metan’.72-74 We used two assumptions for heterogeneity to test the robustness of 
results to different assumptions: comparison-specific heterogeneity and common 
heterogeneity across all comparisons.71  
 
We then fit random-effects NMA models following the approach by Chaimani and 
White, executed using the STATA ‘stataNMA’ package.74-76 We first assumed 
consistency and a common heterogeneity across all comparisons in the network. When 
evidence of statistical inconsistency was detected, we also fit an inconsistency model and 
compared the model fit.  
 
We estimated the probabilities for each intervention to achieve each possible rank among 
all interventions (i.e. being the most effective, the second most effective, all the way till 
the least effective).32,74 We plotted a cumulative ranking curve for each intervention. The 
SUCRA (surface under the cumulative ranking curve) value represents the probability an 
intervention is among the top X of all interventions compared.32,74 
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Evaluating NMA assumption 
We first evaluated the assumption of transitivity qualitatively. Transitivity indicates the 
indirect estimates are valid estimates of the unobserved direct comparisons through 
transitive comparators.29,31 Transitivity is violated when: the anchor treatment differs 
systematically between trials; the choice of the comparison is associated with relative 
effectiveness; treatments included have different indications.31 We considered the 
interventions analyzed in the networks to have the same indication because we only 
included first-line glaucoma medications. 
 
We then evaluated the assumption of consistency statistically (i.e., the agreement of 
direct and indirect estimates) using three approaches: loop-specific approach, modeling 
inconsistency approach, and side-split approach76-81, executed using the STATA 
‘stataNMA’ package.74-76  
 
When evidence of statistical inconsistency was found, we examined the accuracy of data 
extraction and the trial characteristics that may influence the effect estimates, including 
the outcome specification, the funding source, the type of analysis, and other 
characteristics. We conducted sensitivity analysis by removing trials that were suspected 
to have introduced statistical inconsistency.29 
 






3.1 Identification of trials 
We identified 115 trial reports from searching bibliographic databases (Appendix 2), 28 
from Drugs@FDA, and 27 from ClinicalTrials.gov (Figure 1). These 170 reports 
described 139 unique trials. Figure 2.1 and Table 2 show the extent of overlap of trials 
among these three data sources. 
 
Only 78% (132/170) trial reports (or 121/139 unique trials) provided sufficient data for 
pairwise meta-analysis and NMA of IOP at 3 months, the outcome on which these drugs 
were approved (Figure 2.2). This is particularly concerning for pivotal trials identified 
from Drugs@FDA (57%, 16/28). Data needed for meta-analysis were least complete for 
trials identified from ClinicalTrials.gov (33%, 9/27).  
 
3.2 Characteristics of included trials 
Because the goal is to compare and assess the usefulness of different data sources for 
providing data for a systematic review and NMA, we describe the characteristics of 
included trials below by data source (and thus 170 trial reports in total instead of 139 
unique trials).  
  
Years and size of the trials 
The characteristics of 170 included trial reports are described in Table 3. Trials identified 
from bibliographic databases were published between 1983 to 2016 (median=2002). 
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Trials identified from the Drugs@FDA were submitted to FDA for regulatory review 
between 1997 and 2012 (median=2000). Trials identified from ClinicalTrials.gov were 
completed (i.e., completed final data collection for primary outcome) between 1993 and 
2014 (median=2009). There were no ongoing or terminated trials relevant to our analysis. 
 
A total of 29,158 participants were studied in these 139 unique trials (170 trial reports) 
with a sample size ranging from 17 to 1,159. The median sample size of trials from 
bibliographic databases, Drugs@FDA and ClinicalTrials.gov was 111 (Interquartile 
range (IQR), 50-260), 350 (IQR,186-573), and 267 (IQR, 163-586) respectively. 
Although only a small number of trials were identified from the Drugs@FDA and 
ClinicalTrials.gov, trials identified from these two data sources are larger in size: trials 
from each source contributed about one third of all participants (11,417 and 10,145 
respectively). However, data from one quarter (25%, 7,167/29,158) of participants from 
these two sources were not published.  
 
Regions in which participants were recruited 
Most trials were multicenter trials. Trials identified from bibliographic databases reported 
recruiting participants from broader geographic regions than trials identified from the 
Drugs@FDA and ClinicalTrials.gov; the latter two reported recruiting participants 
primarily from North America and Europe. 
 
Specifically, 73/115 trials identified from bibliographic databases reported region(s) from 
which participants were recruited. Of them, 63% (46/73) reported North America, 26% 
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(19/73) reported Europe, 21% (15/73) reported Asia, 4% (3/73) reported Latin America, 
5% (4/73) reported Oceania, and 1% (1/73) reported Africa. 
 
Twenty-six of 28 trials identified from the Drugs@FDA reported region(s) from which 
participants were recruited. Of them, 88% (23/28) reported North America, 15% (4/28 ) 
reported Europe, 4% (1/28)reported Asia, 4% (1/28) reported Latin America, 4% (1/28) 
reported Oceania, and 0% (0/28) reported Africa. 
 
Twenty-four of 27 trials identified from ClinicalTrials.gov reported region(s) from which 
participants were recruited. Of them, 79% (19/24) reported North America, 21% (5/24) 
reported Europe, 0% (0/24) reported Asia, 0% (0/24) reported Latin America, 0% (0/24) 
reported Oceania, and 0% (0/24) reported Africa.  
 
Eligibility criteria 
Ocular hypotensive medication was allowed at enrollment in most trials, yet a washout 
period was not always required in these trials. Specifically, 82% (94/115) trials identified 
from bibliographic databases reported allowing enrollment of participants who were 
taking ocular hypotensive medication on enrollment, and 83% (78/94) of which reported 
requiring a washout period before randomization. Eight nine percent (25/28) of trials 
identified from the Drugs@FDA reported allowing enrollment of participants who were 
taking ocular hypotensive medication on enrollment, and 88% (22/25) of which reported 
requiring a washout period before randomization. Fifty nine percent (16/27) of trials 
identified from ClinicalTrials.gov reported allowing enrollment of participants who were 
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taking ocular hypotensive medication on enrollment, and 63% (10/26) of which reported 
requiring a washout period before randomization.  
 
Follow-up time 
The median length of follow-up was 3 months. The reported duration of follow-up ranged 
from 1-73 months (median=3 months) for trials identified from bibliographic databases, 
1-15 months (median=3 months) for trials identified from the Drugs@FDA, and 1-12 
months (median=3 months) for trials identified from ClinicalTrials.gov. 
 
Type of analysis 
The reporting of type of analysis was poor in trials identified from bibliographic 
databases and ClinicalTrials.gov - only 55% (63/115) and 59% (16/27) respectively 
provided information, as compared to 89% (25/28) trials identified from the 
Drugs@FDA. When such information was available, intention-to-treat analysis was the 
most commonly reported analysis. Intention-to-treat analysis was reported in 65% 
(41/63) trials identified from bibliographic databases, 84% (21/25) trials identified from 
the Drugs@FDA, and 16% (13/81) trials identified from ClinicalTrials.gov. 
Qualitative analysis of transitivity assumption 
We did not find systematic difference of the anchor treatment between trials in terms of 
drug concentration, dosage, or duration of treatment, nor did we find evidence suggesting 
that the choice of the comparison is associated with relative effectiveness. Timolol, the 
most commonly used comparison intervention among the included trials, was compared 
with all other drugs directly in at least one trial.   
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3.3 Risk of bias assessment (Table 4, Figure 3) 
Assessing the risk of bias is challenging for trials identified from Drugs@FDA and 
ClinicalTrials.gov because details describing the design and conduct were generally not 
available from these two sources.  
 
Most trials did not report random sequence generation and allocation concealment 
(unclear risk of bias). For trials identified from ClinicalTrials.gov, the percentage of non-
reporting was 100% (27/27) and 100 % (27/27) for each domain, respectively. For trials 
identified from Drugs@FDA, the percentage of non-reporting was 93% (26/28) and 93% 
(26/28) for each domain, respectively. For trials identified from bibliographic databases, 
the percentage of non-reporting was lower: 54% (62/115) and 65% (75/115) for each 
domain, respectively. 
 
When masking was reported, the study participants and IOP assessors were not masked 
(high risk of bias) in some trials: 21% (24/115) and 10% (11/115) of trials identified from 
bibliographic databases, respectively; 30% (8/27) and 4% (1/27) of trials identified from 
ClinicalTrials.gov. For trials identified from Drugs@FDA, the percentages were lower: 
7% (2/28) and 7% (2/28), respectively. In addition, many trials (>70%) reported single, 
double or triple masking, but did not specify the role of person who was masked.  
 
Most trials were funded by pharmaceutical industry, especially for trials identified from 
Drugs@FDA (100%, 28/28) and ClinicalTrials.gov (93%, 25/27). For trials identified 
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from bibliographic databases, the percentage reported funding from pharmaceutical 
industry was lower (56%, 65/115). 
 
3.4 Comparison of reporting of key characteristics of trials 
When reports of the same trial were identified from more than one source, we compared 
the information on PICOT (patient population, intervention, comparison, primary and 
secondary outcomes, and time points), statistical methods, baseline characteristics, and 
results. A list of all characteristics we compared is available in Tables 5-8. We highlight 
noticeable differences in the text below. 
 
3.4.1 Bibliographic databases vs Drugs@FDA vs ClinicalTrials.gov (Table 5) 
Only four trials (reported in three journal articles) allowed this three-way comparison. 
We found that journal articles identified from bibliographic databases and approval 
packages identified from Drugs@FDA generally provided more information in terms of 
participants, trial design, statistical methods, and results than trial registrations identified 
from ClinicalTrials.gov. 
 
Trial registrations tended to provide information concerning only the primary outcome of 
the trial and adverse events, while journal articles and approval packages also provided 
information on secondary outcomes.  
 
Sample size calculation was reported only in journal articles. Participant flow diagram 
was available from both journal articles and trial registrations, but not from approval 
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packages. Quantitative results of our primary outcome (IOP at 3 months) generally 
agreed among three sources. 
 
3.4.2 Bibliographic databases vs Drugs@FDA (Table 6) 
The comparison of 10 trials identified from both bibliographic databases and 
Drugs@FDA suggested that journal articles generally provided more information 
regarding trial design and statistical methods, while approval packages provided more 
information regarding secondary outcomes of the trials such as visual field, vertical 
cup/disc ratio, central visual acuity.  
The two sources sometimes provided inconsistent eligibility criteria. Some eligibility 
criteria were described in only one source but not both. For example, in one trial (Table 6 
No.5), “intraocular surgery within the past 12 months” was listed in exclusion criteria in 
the journal article [Sall K 2000] but not in the corresponding approval package [CDER 
NDA20816]. 
 
The description of primary outcome and primary analysis of some trials differed between 
the two sources. For example, for one trial (Table 6 No.6), the journal article reported 
mean change in diurnal IOP at 6 months as primary outcome while the approval package 
reported mean IOP averaged over four timepoints (weeks 2, 6 and months 3, 6) as 
primary outcomes. For two trials, per-protocol analysis was reported in the journal 
articles as the primary analysis while intention-to-treat was reported in the approval 




The quantitative results of IOP at 3 months differed substantively for one trial: the journal 
article reported that the mean IOP difference between bimatoprost group and timolol 
group was -1.89 mmHg (95% confidence interval [CI]: -2.70, -1.09) (Table 6 No.4), 
whereas the approval package reported a result of -2.07 mmHg (95% CI: -2.92, -1.23). 
Moreover, for three trials reported in journal articles, outcomes reported in the result 
section were not prespecified in the methods section of the articles, raising concern of 
selective reporting. 
 
3.4.3 Bibliographic databases vs ClinicalTrials.gov (Table 7) 
The comparison for 12 trials showed that half of the trial registrations identified from 
ClinicalTrials.gov had no results at all. For three trials with results posted on 
ClinicalTrials.gov, IOP data were not reported although IOP was among the outcomes 
according to the corresponding journal articles.  
 
Journal articles generally provided more information with regards to trial design, 
statistical methods, and results than trial registrations. However, trial registrations always 
provided patients flow diagram, which was not the case for journal articles. 
 
The two sources sometimes provided inconsistent eligibility criteria. Some eligibility 
criteria were described in only one source but not both. Length of follow-up differed for 
two trials. The number of study groups disagreed for two trials. The specification of 




Type of analysis was described in three trial registrations with much less information 
than what was available from the corresponding journal articles. Methods of handling 
missing IOP data were not described in any trial registrations. 
 
3.4.4 Drugs@FDA vs ClinicalTrials.gov (Table 8) 
Only one trial was identified from both sources. In this case, trial registration provided 
more information than the approval package. The choice of primary outcome differed, 
with the approval package reported mean IOP at a follow-up time point, while the trial 
registration reported mean IOP change from baseline. 
 
Summary 
Taken all together, among the three data sources, journal articles provided the most 
information about trials for systematic review, while trial registration provided the least. 
Approval packages provided more information on secondary outcomes of the trial than 
the other two sources. Trial registrations always provided a patient flow diagram. 
Eligibility criteria disagreed in some cases. The primary outcome and primary analysis 
sometimes disagreed. The quantitative results of IOP at 3 months generally agreed.  
 
Table 9 summarizes the strengths and limitations of each data source for systematic 
review.  
 
3.5 Comparison of quantitative results 
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For the convenience of description of quantitative results, in this section we refer to trials 
identified from bibliographic databases as “published trials”, trial identified from 
Drugs@FDA as “FDA trials”, trials identified from ClinicalTrials.gov as 
“ClincalTrials.gov trials”, trials identified from bibliographic databases but not found on 
Drugs@FDA or ClinicalTrials.gov as “published trials not found on FDA or 
ClincalTrials.gov”. 
 
3.5.1 Pairwise meta-analyses 
Only 121 of the 139 unique trials provided sufficient data for meta-analysis. The 121 
unique trials from all three sources generated 39 direct comparisons. Half of the direct 
comparisons were informed by very few trials: 12 (31%) direct comparisons were based 
on one trial and eight (21%) were based on two trials. For each direct comparison, a 
median number of two trials (interquartile range 1-5.5) were included. There were 110 
(91%) two-arm trials, 10 (8%) three-arm trials, and one (1%) four-arm trial. Timolol, the 
most popular comparator, was studied in 71 (59%) trials. 
 
Table 10.1 shows the summary estimates of mean difference in IOP at 3 months derived 
from pairwise meta-analyses of all unique trials. When compared directly with placebo, 
eight drugs (brimonidine, betaxolol, levobunolol, timolol, levobetaxolol, brinzolamide, 
dorzolamide, and bimatoprost) resulted in statistically significant lower IOP; while there 
was no evidence suggesting unoprostone lowered IOP more than placebo. The estimated 
mean reduction in IOP (vs placebo) ranged from 1.33 to 7.51mmHg. When compared 
directly with timolol, three drugs (bimatoprost, latanoprost, and travoprost) showed better 
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efficacy in IOP reduction, while five other drugs (levobetaxolol, brinzolamide, 
dorzolamide, tafluprost, and unoprostone) did not. The estimated mean difference in IOP 
(vs timolol) ranged from -2.09 to 1.43. The results assuming a common heterogeneity are 
comparable to the results assuming a comparison-specific heterogeneity. 
 
Table 10.2-10.5 and Figure 4 present the pairwise effect estimates (relative to placebo or 
timolol) derived from different networks of trials (published trials, FDA trials, 
ClinicalTrials.gov trials, published trials not found on FDA or ClinicalTrials.gov). The 
effect estimates of these drugs relative to placebo or timolol generally agreed among 
three sources although precision varied. 
 
3.5.2 NMAs 
The number of interventions included differed among different networks: 15 for the all-
unique trial network (121 trials, 20981 participants), 14 for the published trial network 
(107 trials, 17,343 participants), 10 for the FDA trial network (16 trials, 5,250 
participants), and 6 for the ClinicalTrials.gov trial network (nine trials, 2,296 
participants) (Figure 5.1 through 5.4). The all-unique trial network and published trial 
network are well-connected polygons; the FDA trial network is star-shaped (interventions 
were compared to a common comparator but not to one another); the ClinicalTrials.gov 
trial network is a poorly connected. For FDA trial network and ClinicalTrials.gov trial 
network, more than 50% of direct comparisons were based on one trial. (Table 11) 
 
NMA of all-unique trial network 
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Table 12.1 shows the effect estimates generated from NMA that combined direct and 
indirect evidence of all unique trials. In this analysis, we assumed consistency and a 
common heterogeneity across all comparisons in the network. All 14 drugs were more 
efficacious than placebo in reducing IOP at 3 months. The mean reductions (95% CIs) in 
IOP (mmHg) at 3 months, from the most efficacious one to the least, are: bimatoprost 
5.60 (4.90, 6.29), travoprost 4.90 (4.19, 5.61), tafluprost 4.77 (3.53, 6.01), latanoprost 
4.72 (4.09, 5.34), levobunolol 4.54 (3.80, 5.29), timolol 3.73 (3.17, 4.28), carteolol 3.46 
(2.41, 4.51), brimonidine 3.00 (2.28, 3.71), brinzolamide 2.91 (2.11, 3.71), levobetaxolol 
2.53 (1.42, 3.65), dorzolamide 2.33 (1.64, 3.01), betaxolol 2.27 (1.60, 2.95), 
apraclonidine 2.00 (0.28, 3.72), unoprostone 1.86 (1.06, 2.66).  Bimatoprost led to a 
statistically significant lower IOP at 3 months than any other drugs except tafluprost, 
where the two confidence intervals overlapped.  
 
The probabilities for each drug (plus placebo) to achieve each one of the 15 possible 
ranks are present in Figure 6.1, arranged from the least efficacious drug to the most 
efficacious drug. The ranking probabilities are consistent with the treatment effect 
estimates. For example, bimatoprost has a 90.5% probability of being ranked as the most 
efficacious intervention, while placebo has a 98.9% probability of being ranked as the 
least efficacious.  
 
The cumulative rankings for each drug are plotted in Figure 7.1. For each of the 15 
interventions (14 drugs plus placebo) included in the all unique trial network, the X axis 
presented the possible ranks (in this case, it ranges from 1 to 15), and the curve plotted 
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the cumulative probability that a drug is among the top x treatment. If a drug has a 100% 
probability to be the best, the curve would rise and plateaued at the first rank, and the 
SUCRA (surface under the cumulative ranking curve) value would be one. On the 
opposite, if a drug has a 100% probability of being the worst, the curve would level out 
and not rise till the 15th rank, the SUCRA value would then be zero. The SUCRA values 
and mean ranks are consistent with the treatment effect estimates (Table 13). For 
example, bimatoprost has the highest SUCRA value of 99.3 and the highest mean rank of 
1.1, while placebo has the lowest SUCRA value of 0.1 and the lowest mean rank of 15. 
Of note, relative ranking should not be over-interpreted as small differences in effect 
estimates may not be clinically important. 
 
NMAs of other trial networks 
The results of NMAs derived from different sources (published trials, FDA trials, 
ClinicalTrials.gov trials, published trials not found on FDA or ClinicalTrials.gov) are 
presented in Table 12.2-12.5, Figure 6.2-6.5, Figure 7.2-7.5. The effect estimates of 
comparative effectiveness of these drugs generally agreed among three sources although 
precision varied. 
 
Figure 8 presents the treatment effect estimates relative to timolol based on NMAs of 
different networks. The effect estimates generally agreed among different sources 
although precision varied. Of note, for bimatoprost, travoprost, and brinzolamide, where 
NMAs of published trials and the FDA trials found statistically significant differences 
from timolol, NMA of ClinicalTrials.gov trials failed to detect significant differences. 
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This was likely due to small number of trials (and thus low power) included in the 
ClinicalTrials.gov network.  
 
Table 13 displayed the SUCRA values and mean ranks generated by NMAs. The relative 
ranking generally agreed among different sources. Compared to the rankings of 15 
interventions generated by NMA of all unique trials, NMA of FDA trials produced the 
same relative rankings for the 10 available interventions. NMA of published trials 
produced the same relative rankings for the 14 available interventions with a position 
switch between dorzolamide and betaxolol. Noticebly, NMA of ClinicalTrials.gov trials 
produced different relative rankings for the six available interventions with two position 
switches - between bimatoprost and travoprost, and between brimonidine and 
brinzolamide, respectively. 
 
For both pairwise and network meta-analysis, the results from published trials that were 
not found on FDA or ClinicalTrials.gov are similar to those from all published trials, but 
with reduced precision. 
 
3.5.3 Evaluation of inconsistency 
We assessed inconsistency between direct and indirect evidence using three different 
approaches (Appendix 3). Inconsistency assessment was not applicable to 
ClinicalTrials.gov trial network because there was no closed loop, i.e., no direct vs 
indirect evidence. Inconsistency assessment was also not applicable to FDA trial network 
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We used loop-specific approach to estimate an inconsistency factor (IF) for each closed 
loop in the all-unique trial network. We assumed a common heterogeneity for all 
comparisons within each loop but different heterogeneity across loops. We found 36 
triangular loops and 13 quadratic loops. Evidence of statistical inconsistency was 
detected in three (8%) triangular loops.   
 
In order to explore potential reasons for statistical inconsistency, we examined 
characteristics of trials involved in these tree triangular loops. We identified three trials 
that were outliers with larger effect size than the other trials examining the same 
comparisons. All three trials were published trials, two of which were published before 
1990. IOP was measured at 9 months post treatment for one trial. The funding source was 
unclear for two trials, and was pharmaceutical industry for the third trial. All three trials 
did not specify the type of analysis used for primary outcome. The different time points 
of outcome measurement and the unclear type of analysis may have resulted in larger 





We detected evidence of statistical inconsistency in the same three (9%) triangular loops 
in the published trial network. We addressed the inconsistency by conducting a 
sensitivity analysis removing these three trials (see 5.4). 
 
Modeling inconsistency 
We applied a design-by-treatment interaction inconsistency model to check for overall 
inconsistency in the all-unique trial network. We found inconsistency at the overall level 
with a P value of 0.0038. When the inconsistency model and consistency model were 
compared using both Akaike Information Criterion (AIC) and Bayesian Information 
Criterion (BIC) for model fit, inconsistency model did not improve the model fit. We also 
detected evidence of overall inconsistency in published trial networks. Similarly, 
inconsistency models did not improve the model fit. We therefore chose consistency 
model over inconsistency model as our final model.  
 
Side-split approach (node-split approach) 
We used side-specific approach to estimate local inconsistency in the all-unique trial 
network. Evidence of statistical inconsistency was found in two (5%) sides. These two 
sides (levobunolol vs placebo and timolol vs levobunolol) were from one of the three 
triangular loops where loop-specific inconsistency was detected (see 5.3.1). We found 





We detected evidence of statistical inconsistency in all-unique trial network and 
published trial network. We fit inconsistency models which did not improve the model 
fit. We explored the potential source of statistical inconsistency by qualitative analysis. 
We address the inconsistency by sensitivity analysis removing three susceptible outlier 
trials (see 5.4). 
 
3.5.4 Sensitivity analysis  
For sensitivity analysis, we re-analyzed the all-unique trial network after removing 3 
trials that were outliers and that may have introduced heterogeneity and inconsistency. 
We did not conduct sensitivity analysis for other networks because of the small number 
of trials included in those networks. The effect estimates and ranking probabilities from 








In this study, we tested the feasibility of a “rapid” NMA approach, in which trials were 
identified from Drugs@FDA and ClinicalTrials.gov. We found that compared to using all 
unique trials identified from all three data sources (bibliographic databases, 
Drugs@FDA, and ClinicalTrials.gov), using trial from Drugs@FDA alone, we were able 
to generate reasonably precise effect estimates and the same relative rankings for 
available interventions. However, using trials from ClinicalTrials.gov alone, we were not 
able to generate precise effect estimates or consistent ranking.  
 
Rapid approach with limited search is feasible for NMA 
Our findings support that rapid approach with limited search is possible for NMA for 
drug interventions. The results of NMA may be more robust (less sensitive) to the change 
in the number of trials included. In our case, the FDA trial network contains fewer trials 
than all-unique trial network (16 vs 121). However, the effect estimates and the relative 
rankings produced by these two networks are consistent for the available interventions. 
There are two possible explanations for this. First, in the FDA trial network, drugs were 
indirectly compared through a common comparator timolol. The network is no longer a 
well-connected polygon but a radiant star. The star-shaped network raised less concern 
over the assumption of transitivity. Second, the potential bias might be mitigated through 
the common comparator.74 That is, if industry sponsored trials were biased in favor of 
new drugs as compared to timolol, the indirect comparisons among multiple new drugs, 
which were connected through timolol, could be less biased.  
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Drug@FDA is a useful data source for rapid NMA  
FDA approval packages have been used by previous studies as “gold standard” to 
examine selective reporting and its impact on meta-analysis including NMA.64,67,82,83 Our 
study advances previous research by illustrating that Drugs@FDA is a valid data source 
for rapid NMA. Based on our findings, conducting a rapid NMA with trial data from 
FDA approval packages would be an efficient choice for decision-makers who need a 
quick snapshot of comparative effectiveness of approved drugs for a condition. Since 
these trials were conducted under FDA’s jurisdiction, their protocols and analyses were 
reviewed by FDA. Compared to searching bibliographic databases, identifying trials from 
Drugs@FDA requires much less time and resource. The search itself is straightforward as 
only drug generic name is needed.  
 
In addition, we found that approval packages from Drugs@FDA provided more detailed 
information with regards to secondary outcome and adverse events of trials than 
bibliographic databases and ClinicalTrials.gov. It has been shown that published trial 
reports of drug interventions may exaggerate benefit and downplay harms compared to 
internal reports and regulatory documents: outcomes were selectively reported; numbers 
of adverse events were understated; serious adverse events including deaths were 
omitted.84-89 ClinicalTrials.gov only requires reporting of “serious adverse events and 
other adverse events that exceed a threshold of 5% within comparison group”.53 The 
addition of FDA approval packages to published data has revealed increased harm in 
meta-analyses.82 Therefore, our findings are of interest to systematic reviewers as 
Drugs@FDA is a valuable source to tap into for research of regulated drugs. 
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However, one caveat of Drugs@FDA is that not all approval packages are readily 
available from Drugs@FDA and the information presented in the approval packages may 
be limited or incomplete for meta-analysis. As noted earlier, approval packages are 
available on the agency’s website for drugs approved since 1997;44 for drugs approved 
before 1997, information must be requested through a freedom of information request 
(https://www.accessdata.fda.gov/scripts/foi/FOIRequest/requestinfo.cfm). In our study, 
we could not retrieve approval packages for levobunolol, apraclodine, and cartelol, which 
were approved by FDA in 1985, 1987, and 1988, respectively. Our requests for approval 
packages for these three drugs were not responded by FDA In addition, the precision 
measures for the primary outcome (i.e., IOP at 3 months) of these pivotal trials were not 
reported in 42% of trials, limiting the usefulness of approval packages for NMA.  
 
It also should be noted that approval packages often are available only for the first 
indication approved and not for later indications (although one may request those 
documents, which are usually brief). They are only available for products regulated by 
FDA. Therefore, Drugs@FDA does not include “over-the-counter (OTC) products 
marketed without an application”, “dietary supplements”, “biological products regulated 
by Center for Biologics Evaluation and Research”, or “drugs not approved by FDA”.90 
 
ClinicalTrials.gov, in its current form, may not be very useful for rapid NMA 
We found ClinicalTrials.gov least useful for NMA. Among three data sources, 
ClinicalTrials.gov provided the least complete trial information, despite the purpose of its 
establishment--to provide health care professionals and researchers with easy-to-access 
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clinical study information.91 Most trials completed before the initiation of the website in 
2000 were not available. Trial results collected before the launch of the result database in 
2008 were not available. In our case, 8/27 of the trial registrations identified from 
ClinicalTrials.gov had no results, of them, 7/8 were completed before 2008. Similarly, 
previous studies also have found that less than 50% ClinicalTrials.gov trial registrations 
had reported results.66,68,92-94 
 
In addition, ClinicalTrials.gov only requires summary information about a trial protocol 
and results. Therefore, drug dose and regimen were not available in many trial 
registrations; sample size calculation and ways of handling missing data were not 
available; the results of secondary outcomes and adverse events of trials were incomplete 
compared to their corresponding trial reports from bibliographic databases and 
Drugs@FDA. Similar to the findings of our study, Zarin and colleagues found that 61% 
ClinicalTrials.gov registry records lacked specificity of outcome metric, 24% reported 
results for 90% or less of their participants.95 
 
The search of ClinicalTrials.gov did identify 10 trials (4/10 with sufficient data for meta-
analysis) that were neither published or described in FDA approval packages. These trials 
could have been useful for NMA, had the trial information been complete. Overall, the 
status quo of ClinicalTrials.gov limits its usefulness for NMA. 
 
Can systematic reviews and NMAs be done more efficiently? 
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In an ideal world, all trials (and all reports and related information about trials) should be 
indexed in one place. Findings from trials should be presented in a standardized and 
structured format to facilitate systematic reviews. However, problems need to be 
overcome before systematic reviews and NMAs can be done more efficiently. At the 
current time, searching one data source cannot identify all relevant studies. Trial 
information provided by available data sources are far from complete. In addition, 
disagreements were found among different data sources in primary outcome, sample size, 
and estimates of both benefit and harm effects of drugs.11,58-62,96 
   
In our study, disagreements were found around patient eligibility criteria, choice of 
primary outcome, and primary analysis. The goal of a clinical trial is to demonstrate the 
effectiveness and safety of interventions in a study population. With inconsistent 
eligibility criteria, it is difficult for health care professionals and researchers to interpret 
and apply the trial findings. The inconsistency in describing primary outcome and 
primary analysis is also problematic because results could be cherry-picked by trialists to 
better align with their hypotheses.   
 
With regard to the presentation of information, journal articles and FDA approval 
packages typically are presented in PDF format and information needed for systematic 
reviews must be located and extracted manually. There is no cross-agency or cross-
division standard format for preparing trial summaries that are included in the FDA 
approval packages (personal communication). In our study, we observed variations of 
how trials were described across approval packages. In contrast, ClinicalTrials.gov has 
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standardized and tabulated format for organizing data, which is easier for data extraction 
(although data are incomplete). 
 
Areas for improvement 
For regulatory agencies with an increasingly open attitude towards data sharing, our 
findings shall draw their attention to the scope and quality of trial information to share 
with the public. Bennett and colleagues97 proposed that FDA should consider integrating 
components of the CONSORT (Consolidated Standards of Reporting Trials)98 in its 
description of trials. Trial registration numbers should always be included in the FDA 
approval packages. In addition to approval packages, the recent FDA pilot program of 
sharing CSRs is also a promising step forward.99 
 
CSRs contain unabridged and comprehensive descriptions of the clinical problem, design, 
conduct, and results of clinical trials, following a structure and content guidance 
prescribed by the International Conference on Harmonization.100 CSRs can be 
particularly useful for identifying detailed information about harms (in addition to 
efficacy outcomes). Because the results are in the aggregate form, they are easy to 
analyze and sufficient for most systematic reviews. However, CSRs can be thousands of 
pages in length, which require more time to extract and analyze data than public sources.   
 
For trial registries, our findings highlight the incompleteness of information registered. 
The minimal data elements required are insufficient for understanding the design and 
results of trials for the purpose of systematic reviews. The requirement of trial protocol 
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submission may mitigate this problem. In addition, links to publications should be kept 
up-to-date. In our experience, when trials were registered, not all trials reports were 
linked to the trial registration. In addition, when auxiliary studies were linked to the trial 
registrations, there was no easy way to find out whether the analyses in these studies were 
based on randomized comparisons.   
 
Limitations and strengths 
Our study used first-line glaucoma medication as a case study. We only examined 
regulatory data from Drugs@FDA and registration information from ClinicalTrials.gov. 
Therefore, our conclusions should not be overly-generalized. We recognized that we 
searched the three databases at different time point (March 2014 for bibliographic 
databases, April 2014 for Drugs@FDA, and December 2016 for ClinicalTrials.gov). 
However, only two of the 27 eligible trials we identified from ClincialTrials.gov were 
completed (i.e., completed final data collection for primary outcome) after April 2014. 
Excluding these two trials is unlikely to change our key findings and conclusions. 
 
In terms of strengths, we validated a rapid approach for NMA by comparing it with a 
comprehensive approach which covers both published and unpublished evidence. We 
conducted a full range of comparisons of trial information in PICOT, statistical methods, 
and results. Our study enriched the empirical evidence supporting a rapid approach for 
NMA. Future research should test this approach in other clinical areas; in the assessment 
of long-term clinical outcomes, patient-centered outcomes, and adverse events; and in the 
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A rapid NMA approach using Drugs@FDA to identify trials of drug interventions is 
feasible. In our study, NMA based on trials from Drug@FDA alone provided reasonably 
precise estimates of relative effects. Reporting of trial design and results can be improved 
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Table 2. The extent of trial overlaps among bibliographic 
database, Drugs@FDA, and ClinicalTrials.gov 
  
Legend: 
1. ¶ See Appendix 2 for reference ID 
2. * Trial reports with sufficient data for NMA 
3. § One article, two trials 
4. The number of trial reports identified from bibliographic databases, Drugs@FDA, and ClinicalTrials.gov 
is 115, 28, 27 respectively. 
5. Color coding:  
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in each eye must be 
less than or equal to 
36 mmHg at all 
times. These IOP 
criteria must be met 
at both Eligibility 

















be 24 to 36 mmHg, 
inclusive, in at least 
one eye, the same 
eye, at the 8:00 a.m. 
IOP measurements at 
both Eligibility 
Visits 1 and 2. 
Additionally, the 
10:00 a.m. mean IOP 
measurement must 
be 21 to 36 mmHg, 
inclusive, in at least 
one eye, the same 
eye that qualified 
previously. Mean 
IOP measurements 
in each eye must be 
less than or equal to 
36 mmHg at all 
times. These IOP 
criteria must be met 
at both Eligibility 












































































































































































































be 24 to 36 mmHg, 
inclusive, in at least 
one eye, the same 
eye, at the 8:00 a.m. 
IOP measurements at 
both Eligibility 
Visits 1 and 2. 
Additionally, the 
10:00 a.m. mean IOP 
measurement must 
be 21 to 36 mmHg, 
inclusive, in at least 
one eye, the same 
eye that qualified 
previously. Mean 
IOP measurements 
in each eye must be 
less than or equal to 
36 mmHg at all 
times. These IOP 
criteria must be met 
at both Eligibility 










































































































































































































Inclusion: had a post 
washout or untreated 
IOP>=22mmHg and 
=<30mmHg in the 
eligible eye(s) at one 
or more time points 
during the baseline 
12-hour diurnal IOP 
elevation. In subjects 
with bilateral POAG 
or OH, both eyes had 
to meat IOP criteria 
at the same baseline 
12-hour diurnal time 
point. Exclusion: 
difference in IOP 
measurements at any 
one time point 
during the baseline 
12-hour diurnal IOP 
elevation was greater 
than 5 mmHg 
between eyes in 
subjects diagnosed 












































































































































































































washout or untreated 
IOP>=22mmHg and 
=<30mmHg in the 
eligible eye(s) at one 
or more time points 
during the baseline 
12-hour diurnal IOP 
evaluation. For 
subjects with 
bilateral POAG or 
OH, both eyes had to 
meet IOP criteria at 
the same baseline 
12-hour diurnal time 
point. Exclusion: the 
difference in IOP 
measurements at any 
one time point 
during the Baseline 
12-hour diurnal IOP 
elevation was greater 
than 5 mmHg 
between eyes in 
subjects with 





















































NA NA NA morning IOP of 23 
to 34 mmHg, 
inclusive at baseline 
visit after washout of 
prior therapy for 
glaucoma or OHT 
with no more than a 
5 mmHg difference 
between eyes 































































































































































































eye(s) must have 24 
to 36 mmHg IOP at 
8AM on both 
eligibility visit days, 
21 to 36 mmHg 
mean IOP at 10AM 
and 4PM on both 
eligibility visit 
days(the mean IOP is 
the average of two 
IOP measurements 
in the same eye); the 
same eye(s) must 
qualify at both 
eligibility visits; the 
mean IOP in either 
eye at any eligibility 
exam visit must not 











































eye(s) must have 24 
to 36 mmHg IOP at 
8AM on both 
eligibility visit days, 
21 to 36 mmHg 
mean IOP at 10AM 
and 4PM on both 
eligibility visit days 
(the mean IOP is the 
average of two IOP 
measurements in the 
same eye); the same 
eye(s) must qualify 
at both eligibility 
visits; the mean IOP 
in either eye at any 




















































































































































































must not be greater 
















eye(s) must have 24 
to 36 mmHg IOP at 
8AM on both 
eligibility visit days, 
21 to 36 mmHg 
mean IOP at 10AM 
and 4PM on both 
eligibility visit 
days(the mean IOP is 
the average of two 
IOP measurements 
in the same eye); the 
same eye(s) must 
qualify at both 
eligibility visits; the 
mean IOP in either 
eye at any eligibility 
exam visit must not 







































































































































































































eye(s) must have 24 
to 36 mmHg IOP at 
8AM on both 
eligibility visit days, 
21 to 36 mmHg 
mean IOP at 10AM 
and 4PM on both 
eligibility visit days 
(the mean IOP is the 
average of two IOP 
measurements in the 
same eye); the same 
eye(s) must qualify 
at both eligibility 
visits; the mean IOP 
in either eye at any 
eligibility exam visit 
must not be greater 
























































































































































































































Entry mean IOP of 
24 to 36 mmHg, 
inclusive, in one eye, 
the same eye, at the 
post washout 8AM 
IOP measurement at 
both Eligibility 
Visits I and 2. 
Additionally, the 
10AM, 12N, 4PM, 
and SPM mean IOP 
measurements must 
be 21 to 36 mmHg, 
inclusive, in one eye, 





Visits I and 2 must 
be Jess than or equal 
to 36 mmHg at all 
times. 



































Baseline (day 0) 
hour 0 IOP of >= 23 
mm Hg and <= 34 
mm Hg in each eye 
and asymmetry of 
IOP not greater than 
































Day 0, hour 0 
IOP >= 22 mm Hg 


































































































































































































Day 0, hour 0 
IOP >= 22 mm Hg 






































IOPs of greather than 
or equal to 23 mmHg 
and less then or 
equal to 34 mmHg in 
each eye and 
asymmetry of IOP 
between the eyes not 
greater than 5 
mmHg; 8PM IOP on 
Day 0 more than 4 






























NA NA NA Post-washout 
IOP>=23mmHg and 
=<34mmHg in each 
eye and between-eye 





































































































































































































Day 0 IOP at 8 AM 
greater than or equal 
to 23 mm Hg and 
less than or equal to 
34 mm Hg in each 
eye and asymmetry 
of IOP between the 
eyes not greater than 


































Baseline (day 0, hour 
0), IOP >=22 mm Hg 
and <=34 mm Hg in 
each eye and 
asymmetry of IOP 


























Baseline (day 0, hour 
0), IOP >=22 mm Hg 
and <=34 mm Hg in 
each eye and 
asymmetry of IOP 
not greater than 5 
mm Hg. 












1. * Only showing drugs eligible for our systematic review 
2. NA: not applicable 
3. NR: not report 














































































































































































in both eyes 


























in both eyes 














































at least one 
continuous month 
prior to Visit 1. 



































NA NA NA IOP controllable 
and stable on the 
study medication 






































































































































































































































































































































































 IOP higher than 22 

























































































































































































Inclusion criteria: a 
mean (or median) 
IOP of >=23 and 
=<36 in at least one 
eye at the 08:00 
hour time point at 
the Baseline Visit. 
Patient has <5 
mmHg difference 
in mean (or 
median) IOP 
between eyes at 
each time point 
(0800 hours, 1000 
hours, and 1600 
hours) at Baseline. 
Exclusion Criteria: 
Patient has a mean 
(or median) 
IOP >36 mmHg in 
either eye at the 
Screening Visit or 
at any time point 
(0800 hours, 1000 
hours, and 1600 








Yes Yes Can't 
tell 







































NA NA NA Latanopro
st; 
Timolol 
Yes No Can't 
tell 


































































































































































































Mean IOP >36 











Yes Yes Can't 
tell 






























































































Yes Yes Multi 
(63) 









NA NA NA Intraocular pressure 
(IOP) between 19 
mmHg and 35 
mmHg in at least 
one eye, which 
































IOP within the 
protocol-specified 
range at both the 
Eligibility 1 and 2 
Visits. Mean IOP 
must not be >36 




















1. * Only showing drugs eligible for our systematic review 
2. NA: not applicable 
3. NR: not report 
















double or triple 
masking, but did 
not specify the 
role of person 




1 NR NR NR NR Yes Yes 
2 
Randomly numbered 
with a unique code by 
a third party 
Each patient, in sequence, 
was assigned a study 
number corresponding to 
a test drug. The code was 
broken at the end of the 
study. Yes Yes No NR 
3 NR NR NR NR Yes Yes 
4 NR NR NR NR Yes NR 
5 NR NR NR NR Yes NR 
6 NR NR NR NR Yes NR 
7 NR NR Yes NR Yes NR 
8 NR NR Yes NR Yes Yes 
9 NR NR NR NR Yes NR 
10 NR 
Patients were then 
randomly assigned in a 
double-masked fashion to 
one of two treatment 
groups. NR NR Yes Yes 
11 NR NR Yes NR Yes NR 
12 NR NR NR NR Yes NR 
13 NR NR Yes Yes No NR 
14 
The treatment 
assignment was done 
in stratified groups 
based on the patient's 
baseline IOP and the 
number of eyes which 
were entered in the 
study. 
The randomization list 
was kept by the research 
secretary, and the 
examining physician did 
not know to which group 
a newly recruited patient 
would be assigned. No Yes No Yes 
15 NR NR NR NR Yes Yes 
16 NR 
The randomization list 
was kept by each 
controller until the end of 
the study. NR NR Yes NR 
17 NR NR No NR No Yes 
18 NR NR Yes NR Yes NR 




randomly, i.e. each 
new patient entering 





randomly, i.e. each new 
patient entering the study 
received the next-
numbered, masked bottle. NR NR Yes Yes 
21 
The containers were 
confirmed as 
indistinguishable, and 
allotted in a 
randomized manner by 
the controller. The key 
code table was 
retained by the 
controller. 
The containers were 
confirmed as 
indistinguishable, and 
allotted in a randomized 
manner by the controller. 
The key code table was 













double or triple 
masking, but did 
not specify the 
role of person 




22 NR NR Yes NR Yes Yes 
23 NR NR NR NR Yes NR 
24 NR NR NR NR Yes Yes 
25 NR NR No NR No NR 
26 NR NR NR NR No NR 
27 
The patients were 
allocated to treatment 
groups according to a 
computer-generated 
scheme prepared by 
Pharmacia. NR Yes NR Yes Yes 
28 
Subjects were then 
placed on either 
placebo or timolol 
drops in both eyes 
twice a day in a double 
masked manner using 
randomized number 
tables. NR Yes Yes No Yes 
29 NR NR Yes NR Yes Yes 
30 NR NR NR NR Yes Yes 
31 NR NR Yes NR Yes NR 
32 NR NR Yes NR Yes NR 
33 NR NR NR NR Yes NR 
34 NR NR Yes NR Yes Yes 
35 
The patients were 
allocated to different 
treatment groups 
according to a 
pregenerated 
randomization list. NR NR NR Yes Yes 
36 Envelope method Envelope method NR NR No NR 
37 NR NR NR NR Yes NR 
38 NR NR NR NR Yes Yes 
39 
The randomization 
was stratified for 
center and performed 
in blocks of six 
consecutive patients 
within each center. NR NR NR Yes NR 
40 
Patients with an IOP 
of greater than or 
equal to 24 mm Hg in 
at least one eye (the 
same eye) at hours 0 
and 2 were then 
randomly assigned, 
according to a 
computer-generated 
allocation schedule. NR Yes NR Yes NR 
41 
The patients were 
allocated to the 
treatment groups 
according to a 
computer-generated 
list prepared by 
Pharmacia &  Upjohn 













double or triple 
masking, but did 
not specify the 
role of person 







generated for each site 
using SAS (Version 
6.08; SAS Institute, 
Cary, NC) procedure, 
PROC PLAN. 
Patients were assigned 
sequentially to masked 
treatment according to a 
randomization schedule 
generated by the study 
sponsor (Allergan, Inc). 
Each bottle of test 
medication was coded 
with a  shipment number 
and labeled with a study 
number. Each time a 
bottle was dispensed to a 
patient, the tearoff 
portion of the label was 
attached to the patient's 
case-report form. Yes Yes No Yes 




All clinical supplies were 
labeled based on a 
computer-generated 
randomization code and 
dispensed in numerical 
sequence to patients at 
each investigational site. Yes NR Yes Yes 
45 
Patients randomly 
(according to a 
computer-generated 
allocation schedule) 
received one of the 
following masked 
treatment regimens for 
3 months 
All study medication was 
packaged in identical 
bottles by allocation 
number Yes NR Yes Yes 
46 NR NR No Yes No NR 
47 NR NR NR NR Yes Yes 
48 NR NR NR NR Yes NR 
49 NR NR No No Yes Yes 
50 NR NR No No No Yes 
51 NR NR Yes NR Yes Yes 





numbers (0 = receive 
latanoprost in the right 
eye and unoprostone 
in the left eye, 1 = 
receive unoprostone in 
the right eye and 
latanoprost in the left 




medication that was 
packaged in identical 




Patients were dispensed 
study medication that was 
packaged in identical 
bottles according to a 
computer-generated 
randomization list 
provided by Pharmacia & 
Upjohn, Sweden. 













double or triple 
masking, but did 
not specify the 
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Pharmacia & Upjohn, 
Sweden. 
were kept in a locked 
cabinet at the study site. 
In the event of an 
emergency requiring 
identification of the 
masked treatment, the 
envelope could be 
opened. No envelopes 






generated using an 
SAS version 6.12 
(SAS Inc., Cary, NC) 
program and stored in 
a locked cabinet. 
The 
treatment identity was not 
revealed at any 









All patients received two 
identical 
DROPTAINER bottles 
labeled with a patient 
number and 
“morning” or “evening” 
according to the 
computer-generated 
randomization schedule 
provided by the 
Biostatistics 
Department at Alcon 
Laboratories Yes NR Yes Yes 
57 
Patients who met the 
eligibility 
criteria were then 
randomized, by a 
computer-generated 
schedule. NR Yes NR Yes Yes 
58 
On the baseline day, 
the patients were 
randomized (by block 
randomization) to two 
parallel study groups. NR No Yes No No 
59 
The method used for 
preparing the 
allocation schedule 
was based on blocked 
randomization, in 
blocks of eight 
allocation numbers. 
Patients were assigned 
allocation numbers at the 
prestudy visit. Drops 
were contained in 
identical bottles marked 
with allocation numbers. 
During the study the 
assignment codes were 
kept in sealed envelopes 
in a locked space at the 
study location, and were 
delivered with unbroken 
seals on completion of 
trial. Yes Yes No Yes 
60 
Patients who met all 
study eligibility 
criteria were assigned 
a patient number and 
Medication description 
was concealed from the 
patient, investigator, and 













double or triple 
masking, but did 
not specify the 
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assigned to one of 
three treatment groups 
in an equal (1:1:1) 
ratio by means of a 
computer generated 
randomization 
schedule prepared by 
the Alcon Biostatistics 
Department. 
Randomization was 
stratified by site to 
ensure balanced 
treatment within each 
site. 
Masked medication was 
packaged in identical 
Drop-Tainers and 
provided to the 
investigators along with 
sealed envelopes 
containing the medication 
description for each 
patient. 
61 
Patients were allocated 
to 1 of 3 treatment 
groups according to a 
computer-generated 
randomization code 
list. A single block 
randomization list was 
generated for the 
entire study. 
Drug was issued 
according to patient 
numbers that were given 
in consecutive order at 
baseline. Medications 
were provided in 
identical coded bottles. 
Study medication was 
shipped to the individual 
study sties in sets such 
that each set was a 
multiple of the block size 
used in generating the 
randomization. NR NR Yes Yes 
62 
Randomization codes 
were generated and 
medical supplies were 




Each center received 
prepackaged clinical 
supplies with patient 
numbers, which were 
allocated sequentially. No NR No Yes 





Medication identity was 
concealed in individually 
sealed envelopes stored at 
the study sites. Yes NR Yes Yes 
65 NR NR Yes NR Yes Yes 
66 
the randomization 
code was maintained 
at the central 
coordination center. NR Yes NR Yes Yes 





allocated patients into 
these two groups by 
assigning patients into 
blocks in sequence of 
registration to the 
center, which was 
determined by the 
investigators. Each 
block consisted of six 
The Central Registration 
System controller 
randomly allocated 
patients into these two 
groups by assigning 
patients into blocks in 
sequence of registration 
to the center, which was 
determined by the 
investigators. Each block 
consisted of six patients 
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masking, but did 
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the order of treatments 
within the block had 
been randomized.  
(three latanoprost, three 
unoprostone) where the 
order of treatments within 
the block had been 
randomized.  
69 NR NR NR NR Yes Yes 
70 NR NR Yes Yes Yes Yes 
71 NR NR No No No NR 
72 
The chief pharmacist 
at Moorfields Eye 
Hospital, who had no 
other direct 
involvement with the 
trial, randomised one 
of the patients in each 
pair to treatment with 
either betaxolol drops 
or placebo drops. The 
fellow member of the 
pair was then allocated 
to the alternative 
treatment arm. 
Randomisation was 
carried out by means 
of randomisation 
tables. 
Each patient was 
assigned drops coded 
either A, B, C or D that 
corresponded to their trial 
number. Yes Yes No Yes 





generated using the 
SAS (version 
6.12) procedure PROC 
PLAN and the printout 
was stored in a 
locked cabinet. NR Yes Yes No Yes 
75 NR NR No Yes Yes NR 
76 NR NR NR NR No NR 
77 
At the baseline visit 






list, to 1 of 2 treatment 




generated using a SAS 
(version 6.12) program 
and stored in a locked 
cabinet until the study 
was completed. 
The randomization 
schedule was generated 
using a SAS (version 
6.12) program and stored 
in a locked cabinet until 
the study was completed. No No Yes Yes 
79 
A computer-generated 
list of random 
assignments decided 
The list was sealed and 
could be opened only 
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masking, but did 
not specify the 
role of person 





patients would receive. 
the study protocol or after 
any serious adverse event 
occurred. 
80 Computer generated 









by Voice Processing 




performed by centralized 
allocation by Voice 
Processing Plus, Inc., via 
an interactive phone 
registration system. NR Yes No Yes 
82 
Randomization was 
obtained at the 
Coordinating Center. 
Each clinical center 
had its own 
randomization list that 





Bottles of drug and 
placebo were given to 
each center according to 
the randomization list. 
Patients were given a 
bottle marked with a code 
label. The allocation code 
was secured at the 
Coordinating Center at 
the office of the Project 
Coordinator. Yes Yes No Yes 





by the study sponsor 
using the PLAN 
procedure in SAS 
version 6.12 (SAS 
Institute Inc, Cary, 
NC). 
Before 
initiation of study 
treatment, each patient 
who qualified 
for entry was assigned a 
patient randomization 
number, which 
was used on all 
documentation.  Yes NR Yes Yes 
85 NR NR NR Yes Yes NR 
86 NR NR NR Yes No No 
87 
Randomization was 
achieved by asking the 
participants to choose 
any number between 1 




and travoprost (n=49) 
groups, respectively. NR NR Yes No NR 
88 
Patients were 
randomized in a ratio 
of 2:1:1 to the FC 
(q.d., mornings), BIM 
0.03% (q.d., 
evenings), or TIM 
0.5% (b.i.d.) using a 
computer- generated 
randomization list 
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masking, but did 
not specify the 
role of person 




Ver- sion 8.2, Cary, 
NC). 
89 NR 
White plastic dropper 
bottles, each labeled with 
a unique patient number. Yes NR Yes Yes 
90 NR NR Yes NR Yes Yes 
91 
A list of random 
numbers 
Standard containers were 
used and they were 
concealed with a study-
specific cover and all 
kept in a standard opaque 
black medicine vial Yes NR Yes NR 
92 
Randomization lists 
were used to 
preallocate treatment 
kits to each patient 
number by personnel 
not involved with the 
management of the 
study. 
Randomization lists were 
used to preallocate 
treatment kits to each 
patient number by 
personnel not involved 
with the management of 
the study.  No No No Yes 
93 
Allocation was based 
on computer-generated 
random numbers and 




Allocation was based on 
computer-generated 
random numbers and was 
concealed by using 
sequentially numbered 





(drugs in code forms), 
generated with the 
help of table of 
randomization, were 
prepared in advance 
by an investigator who 
was not related to the 
study. Whenever, a 
study participant was 
found to be eligible, an 
envelope was opened 
by another person in 
the department and the 
patient was put on the 
allocation plan as 
found inside the 
envelope in coded 
form. 
Fifty opaque envelopes 
containing random 
numbers (drugs in code 
forms), generated with 
the help of table of 
randomization, were 
prepared in advance by 
an investigator who was 
not related to the study. 
Whenever, a study 
participant was found to 
be eligible, an envelope 
was opened by another 
person in the department 
and the patient was put 
on the allocation plan as 
found inside the envelope 
in coded form. Yes No No NR 
95 NR NR NR NR No NR 
96 
These kit 
numbers had been 
randomized by the 
study sponsor using 
statistical software 
(SAS Institute, Cary, 
NC). 
At the study site, the 
enrolling 
clinician assigned a 
number to the patient, 
and then called 
an interactive voice 
response system that was 
hosted by the 
study sponsor in order to 
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schedule, balanced for 
ethnicity and drug 
assignment, was 
produced for each 
participating site by 





the randomization code 
was retained by the study 
sponsor and made 
available to the 
investigators only after 
the study had ended.  Yes No Yes Yes 
99 
Randomization codes 
were generated by 
Pfizer according to 
standard operating 
procedures and were 
kept at Global 
Pharmacy Operations 
(New York, New 




generated. NR No NR Yes Yes 
101 NR NR NR NR No No 
102 
Patients were 
randomized using Proc 
Plan, SAS   for 
Windows (version 8.2; 
SAS Institute Inc., 
Cary, NC). NR Yes NR Yes Yes 
103 NR 
patients were provided 
with identically 
appearing sealed cartons, 
labeled with the patient 
randomization number, 
which contained 
marketed bottles of 
the study medications, 
and patients were 
instructed not to 
disclose their study 
medication to the 
investigator or office 
personnel. No Yes No Yes 
104 NR NR NR NR Yes Yes 
105 NR NR No No No No 
106 NR NR No No Yes NR 
107 
Randomization was 
performed by Ms. 
Takako Komiya... in 
research center, after 
confirming identical 
appearance of both 
treatments. 
Randomization was 
performed by Ms. Takako 
Komiya... in research 
center, after confirming 
identical appearance of 
both treatments.  NR NR Yes Yes 
108 
Patients were assigned 
to treatment using a 
computer-generated 
Personnel at each study 
site used an interactive 
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schedule prepared by a 
statistician at Merck 
determine which masked 
treatment containers 
should be given to which 
patient.  
109 NR NR No NR Yes Yes 
110 NR NR No No No NR 
111 
A list of sequential 
patient numbers was 
generated by a 
member of the sponsor 
programming group 
(SAS Institute) not 
involved in the 
conduct of the study. 
A list of sequential 
patient numbers was 
generated by a member of 
the sponsor programming 
group (SAS Institute) not 
involved in the conduct 
of the study. Study 
medications were 
provided in identical 
bottles. Staff members 
who provided the study 
medications to patients 
did not discuss those 
medications with other 
site personnel. Yes NR No Yes 
112 NR NR NR NR Yes Yes 
113 NR 
A designee at each study 
site, other than 
the investigator, was 
responsible for the 
dispensing study 
treatment No Yes No Yes 
114 
Subjects received 
masked kits for 
2 weeks of study 
medication via an 
interactive voice 




Subjects received masked 
kits for 
2 weeks of study 
medication via an 
interactive voice 
response system using a 
computer-generated 
random 
allocation schedule. Yes NR Yes Yes 
Legend: 
1. ¶ See Appendix 2 for reference ID 
2. NR: not report 
3. IOP: intraocular pressure 
4. Color coding: 
Green Low risk of bias 
Yellow Unclear risk of bias 
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204251   C-09-038 NR NR Yes NR Yes Yes 
204251   C-10-033 NR NR NR NR Yes Yes 
204251   C-10-039 NR NR NR NR Yes Yes 
20816    C-95-46 NR NR NR NR Yes Yes 
20816   C-95-48 NR NR NR NR Yes Yes 
20869   44 NR NR NR NR Yes Yes 
20869   47 NR NR NR NR Yes Yes 
20869   63 NR NR NR NR Yes Yes 
20869   64 NR NR NR NR Yes Yes 
21114   C-97-40 NR NR Yes NR Yes Yes 
21114   C-97-67 NR NR Yes NR Yes Yes 
21114   C-97-80 NR NR Yes NR Yes Yes 
21214   C97-UIOS-
004 NR NR Yes NR Yes Yes 
21214   C97-UIOS-
005 NR NR Yes NR Yes Yes 
21214   C97-UIOS-
003  NR NR Yes NR Yes Yes 
21257    C-97-71 NR NR Yes NR Yes Yes 
21257   C-97-72 NR NR Yes NR Yes Yes 
21257   C-97-79 NR NR Yes NR Yes Yes 
21257   C-97-02  NR NR Yes NR Yes Yes 
21257   C-97-73 NR NR NR NR Yes Yes 
21262   190342-005 
They [the 
investigational 
materials] were coded at 
Allergan using a 
computer-generated 
randomization list. NR NR NR Yes Yes 
21275    192024-
008 NR NR NR NR Yes Yes 
21275    192024-
009 NR NR NR NR Yes Yes 
21275   192024-002 NR NR No NR Yes Yes 
21275   192024-003 NR NR Yes NR Yes Yes 
21275   192024-004  NR NR No NR Yes Yes 
21398   190342-
012T NR 
Each identically 
masked bottle of 
test medication 
was labeled with a 
patient number. Yes No Yes Yes 
21398   190342-
013T NR 
Each identically 
masked bottle of 
test medication 
was labeled with a 
patient number. Yes No Yes Yes 
Legend: 
1. NR: not report 
2. IOP: intraocular pressure 
3. Color coding: 
Green Low risk of bias 
Yellow Unclear risk of bias 
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NCT00277498 NR NR NR NR Yes Yes 
NCT00332384 NR NR NR NR Yes Yes 
NCT00332436 NR NR NR NR Yes Yes 
NCT00539526 NR NR No NR Yes Yes 
NCT00690794 NR NR Yes NR Yes Yes 
NCT00705757 NR NR No NR No No 
NCT00708422 NR NR Yes NR Yes Yes 
NCT00751049 NR NR Yes NR Yes Yes 
NCT00751062 NR NR Yes NR Yes Yes 
NCT00751127 NR NR Yes NR Yes Yes 
NCT00761319 NR NR Yes NR Yes Yes 
NCT00763061 NR NR Yes NR Yes Yes 
NCT00798759 NR NR Yes NR Yes Yes 
NCT00961649 NR NR Yes Yes No Yes 
NCT00991822 NR NR No NR Yes No 
NCT01001195 NR NR No Yes Yes Yes 
NCT01026831 NR NR Yes NR Yes Yes 
NCT01110499 NR NR Yes NR Yes Yes 
NCT01155219 NR NR No No No Yes 
NCT01223378 NR NR No NR Yes Yes 
NCT01253902 NR NR No NR Yes Yes 
NCT01254604 NR NR Yes NR Yes Yes 
NCT01297517 NR NR Yes Yes Yes Yes 
NCT01297920 NR NR Yes Yes Yes Yes 
NCT01310777 NR NR Yes Yes Yes Yes 
NCT01664039 NR NR No Yes No Yes 
NCT02140060 NR NR Yes NR Yes Yes 
Legend: 
1. NR: not report 
2. IOP: intraocular pressure 
3. Color coding: 
Green Low risk of bias 
Yellow Unclear risk of bias 
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Non-comparable 



























Table 5. Comparison of reporting of trials (bibliographic databases vs Drugs@FDA vs 





































































































"Safety population" or 










































































per protocol. "Safety 
population" or "Safety 
analysis" Journal article 
and ClinicalTrials.gov: 
intention-to-treat, 


























B1b-B1m. 1) Inclusion 
criteria 
.Secondary glaucoma. 





Journal article and 
FDA: reported. 
ClinicalTrials.gov: NR. 
2) Exclusion criteria. 
Journal article and 
FDA: ocular surgery 





























































































































Table 5. Comparison of reporting of trials (bibliographic databases vs Drugs@FDA vs 





































    







































































































































































Table 5. Comparison of reporting of trials (bibliographic databases vs Drugs@FDA vs 


























Other outcomes Primary outcome 
Other outcomes 
(from method section 
of Publication) 
Other outcomes 

















































Mean IOP at 
the 3-month 
visit 
at all 4 time 
points. 
1. The mean IOP at the 
2-week and 6-week 
visits for all time 
points. 






dus variables, and 
resting pulse rate and 
blood pressure. 
1. Baseline mean IOP 
levels at each of the 4 
time points.  
 2. percentage 
reduction in IOP 
from baseline to the 
3-month visit.  






fundus variables, and 
resting pulse rate and 
blood pressure. 

























1. Mean IOP at 
baseline, week 2, 6, 
and 12 visit at each of 
the 4 time points. 
2. Mean IOP change 
from baseline at at 
baseline, week 2, 6, 
and 12 visit at each of 
the 4 time points. 
3. AE and SAE.  
4. Cardiovascular 
parameters   




























Other outcomes Primary outcome 
Other outcomes 
(from method section 
of Publication) 
Other outcomes 
































































1.the mean IOP at the 
2- and 
6-week visits for all 
time points. 







and resting pulse rate 
and blood pressure 
1.the mean IOP at the 
2- and 6-week visits 
for all time points. 
2. % IOP reduction 
from baseline. 






fundus parameters, and 
resting pulse rate and 
blood pressure 

















    
1. Mean IOP at 
baseline, week 2, 6, 
and 12 visits at each of 
the 4 time points. 
2. Mean IOP change 
from baseline at at 
baseline, week 2, 6, 
and 12 visits at each of 
the 4 time points. 
3. AE and SAE.  
4. Cardiovascular 
parameters   




























Other outcomes Primary outcome 
Other outcomes 
(from method section 
of Publication) 
Other outcomes 











































at each of the 




























IOP at 8 AM, 
10 AM, 3 
PM, and 5 
PM at weeks 
2 and 6 and 
at months 3, 
6, and 12. 
1.Mean IOP.  
2.The percentage of patients reaching a mean 
daytime IOP of less than 18 mm Hg at all follow-
up visits 
3.The percentage of patients with a mean follow-
up IOP within ( 14, 14-17.5, and  17.5 mm Hg) 
4.The percentage of patients achieving a mean 
daytime decrease from baseline IOP of greater 
than 20% 
5.The safety evaluation included an assessment of 
reported adverse events, biomicroscopy, tests of 
visual acuity and visual fields, ophthalmoscopy, 
cup-disc ratio, heart rate, blood pressure, 
complete blood cell count, serum chemistry, and 
urinalysis. 































IOP at 8 AM, 
10 AM, 3 
PM, and 5 
PM at weeks 
2 and 6 and 
at months 3, 
6, and 12. 
   
Visual field, vertical 
cup/disc ratio, central 
visual acuity. 





















































Other outcomes Primary outcome 
Other outcomes 
(from method section 
of Publication) 
Other outcomes 


















































IOP at 8 AM, 
10 AM, 3 
PM, and 5 
PM at weeks 
2 and 6 and 
at months 3, 
6, and 12. 
1.Mean IOP.  
2.The percentage of patients reaching a mean 
daytime IOP of less than 18 mm Hg at all follow-
up visits 
3.The percentage of patients with a mean follow-
up IOP within ( 14, 14-17.5, and  17.5 mm Hg) 
4.The percentage of patients achieving a mean 
daytime decrease from baseline IOP of greater 
than 20% 
5.The safety evaluation included an assessment of 
reported adverse events, biomicroscopy, tests of 
visual acuity and visual fields, ophthalmoscopy, 
cup-disc ratio, heart rate, blood pressure, 
complete blood cell count, serum chemistry, and 
urinalysis. 































IOP at 8 AM, 
10 AM, 3 
PM, and 5 
PM at weeks 
2 and 6 and 
at months 3, 
6, and 12. 
   
Visual field, vertical 
cup/disc ratio, central 
visual acuity. 

























  NR NR NR NR NR NR 
Legend: 
1. ¶ See Appendix 2 for reference ID 
2. ROB: risk of bias 
3. IOP: intraocular pressure 
4. Color coding: 
M Misleading 
X Substantive difference across reports 
J Difference in completeness across reports, the journal article provides more information 
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F Difference in completeness across reports, the FDA approval package provides more information 
C Difference in completeness across reports, the ClinicalTrials.gov registration provides more information 
E Difference in completeness across reports, each provides some information 
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1 20869  47 39 
Exclusion 
cirteria. Journal 
article: history or 
vevidence of 






































2 20869  63 40 
Inclusion criteria: 






(days -21 to -1) 





acuity worse than 
20/80 in both 
eyes, 
contraindication 
to the use of 
beta-blockers, 
history or 





surgery or trauma 
less than 6 
months from 
study start, laser 















y population" or 
"Safety analysis". 























































surgery less than 
3 months from 
study start, and 
concomitant 
medications 
known to affect 
IOP.FDA:NR. 















Previous use of 














ITT and safety 
population; FDA: 


















4 21275 192024-009 51 
Exclusion 
criteria: FDA: 
Previous use of 

















ITT and safety 
population; FDA: 


























article: had had 
intraocular 














































the past 12 
months or laser 
surgery within 
the past 3 
months; having 
had therapy with 
an investigational 
agent within the 
past 30 days. 
FDA: NR. 










article: had had 
intraocular 
surgery within 
the past 12 
months or laser 
surgery within 
the past 3 
months; having 
had therapy with 
an investigational 
agent within the 
past 30 days. 
FDA: NR. 













64     
Journal article: 
6 month data, 
24 month 
study.  FDA: 


















8 21257 c-97-71 56 
Exclusion 
criteria: FDA: 1) 
any form of 
glaucoma other 
than OAG with 




n component or 
ocular 
hypertension; 2) 

































































the past three 
months. Journal 
article:NR. 
9 21257 c-97-72 60 
1) Inclusion 
criteria: Journal 
article: 21 years 
of age or older. 
FDA: NR.  
2)Exclusion 
criteria: FDA: 
any form of 
glaucoma other 
than OAG with 









the past three 
months. Journal 
article: NR. 












































Table 6. Comparison of trial reporting (bibliographic databases vs Drugs@FDA) Part 1 
details (continued)  
No. 
Drugs@FDA NDA-




















1 20869  47 39   
 Placebo usage Journal 












         
2 20869  63 40   
 Placebo usage Journal 












       




























5 20816 c-95-46 50  
Placebo usage Journal article: 
reported. FDA: NR 










6 20816 c-95-48 44  
Number of participants 
randomized in this study. 
Journal article: reported. 
FDA: NR. Placebo usage 




















































































































































































change in IOP 
from baseline at 
month 3, hour 0 
1.The mean IOP at baseline, week 2, 
month 1, month 2, month 3 of hour 0 and 
hour 2.  
2. The mean and percent of IOP change 
from baseline at each time point. 
3.AE and SAE. 
4. Visual acuity, visual field results, optic 




at week 2, 
month 1, 
month 2, 
month 3 of 












Unclear     
1.The mean IOP 
at baseline, 
week 2, month 
1, month 2, 
month 3 of hour 
0 and hour 2.  
2. The mean and 
percent change 
of IOP reduction 
from baseline at 
each time point. 
3. AE. 




disc ratio, etc. 
NR 
at week 2, 
month 1, 
month 2, 
month 3 of 












change in IOP 
from baseline at 
month 3, hour 0 
1.The mean IOP at baseline, week 2, 
month 1, month 2, month 3 of hour 0 and 
hour 2. 2. The percent mean IOP 
reduction from baseline at each time 
point. 
3.AE and SAE. 
4. Visual acuity, visual field results, optic 
nerve cup-to-disc ratio, etc. 
  NR 
at week 2, 
month 1, 
month 2, 
month 3 of 












Unclear     
1.The mean IOP 
at baseline, 
week 2, month 
1, month 2, 
month 3 of hour 
0 and hour 2.  
2. The percent 
mean IOP 
reduction from 
baseline at each 
time point. 
3. AE.  
NR 
at week 2, 
month 1, 
month 2, 
month 3 of 






























































mean IOP at 8 
am, 10 am, and 4 
pm at week 2, 
















1. Mean IOP 
reductions at 8 
am, 10 am, and 4 
pm at week 2, 
week 6, and 
month 3.  
2. Response rates 
for all target IOPs 
at month 3. 



















at 8 am, 10 
am, and 4 
pm at week 
2, week 6, 
and month 
3 





mean IOP at 8 
am, 10 am, and 4 
pm at week 2, 
week 6, and 
month 3 
    
1. Mean IOP 
reductions at 8 
am, 10 am, and 
4 pm at week 2, 
week 6, and 
month 3. 
2. Response 
rates for all 
target IOPs at 

















at 8 am, 10 
am, and 4 
pm at week 
2, week 6, 
and month 
3 






















































from baseline at 
week 2, week 6, 




visual acuity, and 
visual field. 













density and laser 
flare meter 
readings 
1. Mean IOP at 
each follow-up 
visit.  





target IOP levels 




visual acuity, and 
visual fields. 











ocular safety were 
performed: 
endothelial cell 






































in Mean IOP 








from baseline at 
week 2, week 6, 
and month 3 
    
1. Mean IOP at 
each time point. 




, visual acuity, 
and visual 
fields. 





































































elial cell density 
and laser flare 
meter readings 









trough times at 
month 1, 2, and 3 
1. Percentage of patients whose condition 
responded (IOP reduction>=5 mm Hg) or 
was controlled ((IOP<=21 mm Hg) on 
treatment at each time point. 
2. Mean IOP at each time point.  
3. AE and SAE. 
4. Visual acuity, biomicroscopic 
parameters, funduscopic parameters, and 
visual fields. 5) Pulse and blood pressure, 










at month 1, 





















trough times at 
month 1, 2, and 3 
    
1. Mean IOP at 
each time point. 
2. Mean IOP at 
each time point 
categorized by 
age and gender.  
3. AE.   





visual fields.  








at month 1, 






















trough times at 
month 1, 2, and 3 
1. Percentage of patients whose condition 
responded (IOP reduction>=5 mm Hg) or 
was controlled ((IOP<=21 mm Hg) on 
treatment at each time point. 
2. Mean IOP at each time point. 
3. AE. 
4. Visual acuity, ocular signs, dilated 
fundus parameters, visual fields 
5. Pulse, blood pressure, hematology, 








at month 1, 
































































trough times at 
month 1, 2, and 3 
  
  
1. Mean IOP at 
each time point.  
2. AE.  













at month 1, 
























pressure at 6 
months, defined 




measured at pre 






1. Mean changes from baseline in the 
four individual intraocular pressures. 
2. percentage of patients who responded 
to therapy (that is,defined as having a 
reduction from baseline in 12-hour 
diurnal intraocular pressure >= 15%). 
3. Best-corrected visual acuity, slit-lamp 
biomicroscopy, dilated ophthalmoscopy, 
manifest refraction, visual fields, 
evaluation of iris/eyelid discoloration and 
abnormal eyelash growth, ocular 
symptoms, ocular and nonocular adverse 

























Mea n IOP at 
each time point 
(8am, 10am, 
4pm, 8pm) at 
week 2, 6, 




















































































heart rate, and 
blood pressure. 
8 21257 c-97-71 56 
Journal 
article 
mean IOP at 8 
AM, 10 AM and 
4 PM of week 2, 
month 1.5, 3, 4.5, 
6, 9, 12 for the 
patient’s worse 
eye 
1.  Mean changes from baseline at each 
time points.  
2. The percentage of patients who 
responded to treatment (based on a 30% 
or greater intraocular pressure reduction 
from diurnal baseline or a final 
intraocular pressure of 17 mm Hg or less.  
3。 SAE and AE.  
4. Visual acuity, inflammatory cells and 
aqueous flare, ocular signs, fundus 
parameters, cup-to-disk ratio, or visual 
field parameters, corneal thickness or 
endothelial cell count, cystoid macular 
edema.  
5. Pulse rate, blood pressure hematology, 







at 8 AM, 
10 AM and 
4 PM of 
week 2, 
month 1.5, 
3, 4.5, 6, 9, 
12  





mean IOP and 
mean IOP change 
from baseline at 8 
AM, 10 AM and 
4 PM of week 2, 
month 1.5, 3, 4.5, 







baseline at each 
time points. 
2. SAE and AE.  























at 8 AM, 
10 AM and 
4 PM of 
week 2, 
month 1.5, 







9 21257 c-97-72 60 
Journal 
article 
mean IOP at 8 
AM, 10 AM, and 
4 PM of week 2 
1. The mean IOP at 8 AM,10 AM,and 4 
PM, pooled across visit days.  





at 8 AM, 
10 AM and 
















































month 1.5, 3, 4.5, 




3. The mean changes from baseline at 
8AM, 10AM, and 4PM, pooled across 
visit days.  
4.The percentage of patients who 
responded to treatment (based on a 25% 
or greater intraocular pressure reduction 
from diurnal baseline.  
5. SAE and AE.  
6. Visual acuity, inflammatory cells and 
aqueous flare, ocular signs, fundus 
parameters, cup-to-disk ratio, or visual 
field parameters, corneal thickness or 
endothelial cell count,  cystoid macular 
edema.  
7. Pulse rate, blood pressure hematology, 














mean IOP and 
mean IOP change 
from baseline at 8 
AM, 10 AM, and 
4 PM of week 2 
month 1.5, 3, 4.5, 







baseline at each 
time points.  
2. AE and SAE. 























at 8 AM, 
10 AM and 
4 PM of 
week 2, 
month 1.5, 






10 21257 c-97-79 54 
Journal 
article 
mean IOP at 9 
AM, 11 AM, 
4AM of week 2 
month 1.5, 3, 4.5, 
6, 9.  
1. AE. 
2. Visual acuity, 
ocular hyperemia, 
aqueous flara and 
inflammatory 
























3, 4.5, 6, 9.  















































3. Pulse rate and 
blood pressure 
least 6 mm Hg or 
measured IOP 
was 20 mm Hg or 
lower).  
3. AE.  
4.  Visual acuity, 
ocular hyperemia, 
aqueous flara and 
inflammatory 







5. Pulse rate and 
blood pressure 
Legend: 
1. ¶ See Appendix 2 for reference ID 
2. ROB: risk of bias 
3. IOP: intraocular pressure 
4. Color coding: 
M Misleading 
X Substantive difference across reports 
J Difference in completeness across reports, the journal article provides more information 
F Difference in completeness across reports, the FDA approval package provides more information 
E Difference in completeness across reports, each provides some information 































































































































































































Table 7. Comparison of reporting of trials (bibliographic databases vs ClinicalTrials.gov) 













































B1b-B1m. 1) Inclusion 
criteria. Journal article: 
pigmentary and 
pseudoexfoliative 
glaucoma; the mean IOP 
was required to be 26 
through 36 mmHg in the 
eye with the higher IOP. 
ClincalTrials.gov: NR.  
2) Exclusion cirteria. 
Journal article: any ocular 
filtering surgical 
intervention; "ocular 
procedure within 3 months 
before screening". 
ClincalTrials.gov: NR.  
3) Other eligibility criteria. 
Journal article: yes. 
ClincalTrials.gov: no 












































































Journal article: NR.  
2) Exclusion criteria: 
ClincalTrials.gov: history 
of acute angle closure; 
regular B-adrenergic 
antagonist treatment 
for >3m and/or at any time 
during 6m prior to study 
start. Journal article: NR. 
























B1b-B1m 1) Inclusion 



























































article: Specified that the 
IOP requirement was after 
the discontinuation of any 
existing ocular 
hypotensive treatment. 
ClincalTrials.gov: did not 
specify.  
Prior glaucoma 
medication. Both include 
patient who is drug-naive. 
But ClincalTrials.gov gave 
a definition for drug-naive 
(those who have never 
used or who have not used 
ocular hypotensive 
medication for at least 4 
weeks prior to screening). 
2) Exclusion critetia. Prior 
glaucoma medication.  
Journal article: ocular 
medications (other than 
antiglaucoma medications 
or topical lubricants) 
within 1 week of 
screening. 
ClincalTrials.gov: Patient 
is currently taking two or 
more anti-glaucoma 
medications (except 
Cosopt™ or its generic 
formulation); Patient has 
previously used tafluprost.  
Prior ocular surgery. 
Journal article: history of 
certain ocular surgeries. 
ClincalTrials.gov: Patient 
has had intraocular surgery 
in either eye in the last 4 
months; Patient has a 
history of glaucoma 
surgery or refractive 

































B1b-B1m 1) Inclusion 
criteria. IOP. Journal 
article: the study 
population included 
patients...with an 
intraocular pressure <= 18 
mmHg in both eyes. 
ClincalTrials.gov: NR. 
 2) Exclusion criteria.  

































































medication.  Journal 
article: Systemic 
antiglaucoma treatment 
was not allowed within the 








criteria: Journal article: 
history of refractive 
surgery. ClincalTrials.gov: 
Intraocular surgery or 
glaucoma laser surgery in 
study eye(s) within 3 
months. History of corneal 
refractive laser surgery 
(eg. LASIK, LASEK) in 
study eye(s). 






























B2. Did eligibility criteria 
REQUIRE taking an 
ocular hypotensive 
medication at the time of 
enrollment? Journal 
article: yes. 
ClincalTrials.gov: no.  
B3. Did eligibility criteria 
ALLOW enrolling 
participants if they were 
on ocular hypotensive 















article:Patients at least 18 
years old with a diagnosis 
of openangle glaucoma or 
OHT who had been on 






















































bilateral latanoprost for at 
least 4 weeks were eligible 
for the study. Patients on 
latanoprost and 1 
adjunctive medication at 
screening were also 
eligible, but were required 
to undergo a 4-week 
washout of the adjunctive 
medication before the 
baseline visit. 
ClincalTrials.gov: no.  
2) Exclusion criteria:  
Prior glaucoma 
medication. Journal article: 
use of bimatoprost or 
travoprost within the 
previous 6 months, 
required use of ocular 
medications other than the 
study medications during 
the study (intermittent use 
of BAK-free artificial tears 
was permitted). 
ClincalTrials.gov:no.  
Prior cataract surgery. 
Journal article: history of 
refractive surgery. 





B1b-B1m. 1) Inclusion 
criteria. IOP. Journal 
article: "Subjects were 
eligible if they had an IOP 
of 22–32 mm Hg, and an 
IOP of ≥24 mm Hg for at 
least two of three 
measurements during Visit 
3 (Day 1, baseline), which 
occurred after a 28-day 
washout period in subjects 




2) Exclusion Criteria.  
Angle closure glaucoma. 
Journal article: subjects 
with closed or barely open 
anterior chamber angle or 
a history of acute angle 









































































B3.Did eligibility criteria 
ALLOW enrolling 
participants if they were 
on ocular hypotensive 









1) Inclusion criteria. 
ClincalTrials.gov: Mean 
IOP >36 mmHg in either 
eye at screening. Journal 
article: NR. 
2) Exclusion criteria. 
Journal article: Subjects on 
glaucoma treatment at the 
time of screening visit 
(visit 1) underwent a 
washout of previous 
glaucoma treatment; 
following this, at the 
baseline visit (visit 2), the 
subjects’ mean (or median) 
IOP had to be ≥ 24 and ≤ 
36 mmHg in at least one 
eye at the 08:00 hour time 
point, and there had to be a 
< 5 mmHg difference in 
mean (or median) IOP 
between the eyes at the 
08:00, 10:00 and 16:00 





















medication. Journal article: 
if they had used any ocular 
medications (other than 
latanoprost 0.005% or 
artificial tears) within 
seven days of the 
screening visit. 
ClincalTrials.gov: NR. 
Prior ocular surgery.  
Journal article: prior 
corneal surgery within the 
previous one year; any 
intraocular surgery within 
the previous six months; 






















































any ocular laser surgery 








1) Inclusion criteria. IOP. 
Journal article: >22 mmHg 
in at least one eye. 
ClincalTrials.gov:  >21 
mmHg in at least one eye. 
Age. 
ClincalTrials.gov >19. 

















Table 7. Comparison of reporting of trials (bibliographic databases vs ClinicalTrials.gov) 






Number of study 
groups 
Treatments compared 
Sample size at 
baseline 
Age Sex 










1 NCT00277498 61   
Number of participants 
randomized. Journal 
article: reported. 
ClincalTrials.gov: NR.  
Placebo usage (account 
for different 
administration time of 
latanoprost/combinatio



















      
2 NCT00751049 35   
Number of participants 
randomized. Journal 
article: reported. 
ClincalTrials.gov: NR.  
Placebo usage (account 
for different 
administration time of 
latanoprost/combinatio
n and timolol). Journal 
article: reported. 
ClincalTrials.gov: NR.  



















      




Arms. Journal article: 3 
arms, timolol, 
latanoprost morning 3m 
then evening 3m, 
latanoprost evening 3m 




Number of participants 
randomized. Journal 
article: reported. 
ClincalTrials.gov: NR.  
Placebo usage (account 
for different 
administration time of 




Drug dose. Journal 
article: reported. 


























Number of study 
groups 
Treatments compared 
Sample size at 
baseline 
Age Sex 











ClincalTrials.gov: NR.  
4 NCT00751127 69   












      
5 NCT01026831 108       
Journal article: 
age each arm. 
CT: age in each 
arm and in total 
          
6 NCT01155219 110       
Journal article: 
age in total. CT: 
age in each arm 
and in total 
Journal article: 
sex in total. CT: 
sex in each arm 




: no.  
      
7 NCT01253902 109       
Journal article: 
age in each arm. 
CT: age in each 






      











      
9 NCT01223378 113 
Journal article: 5 
groups. 4 groups 
of one drug; 1 
group of the other 
drug. 
ClincalTrials.gov

























      
10 NCT01254604 114       
Journal article: 
mean and SD of 
age in each arm. 
ClincalTrials.gov
: mean and SD of 
age in each arm 
and in total. 
          
11 NCT00690794 101   










          
12 NCT00991822 98   
Number of participants 
randomized. Journal 
article: 140 (70:70). 
ClincalTrials.gov:160. 
Drug dose.  
ClincalTrials.gov: 
reported. Journal 
article: NR.  





      
133 
 






















Source Primary outcome 
Other outcomes 
(from method section 
of Publication) 
Other outcomes (from results section of 
Publication) 









































The mean IOP 
change from baseline 
at all 9 time points 
during the study 
(08:00, 10:00, and 
16:00 hours at weeks 
2, 6, and 12) 
1. The proportion of patients with a favorable IOP response, defined 
as >=25% reduction in diurnal IOP from baseline at weeks 2, 6, and 12. 
Diurnal IOP was calculated as the mean of the IOPs in the “study eye” at 
the 3 time points for each clinic visit (08:00, 10:00, 16:00 hours). 
2.  The mean change from baseline in diurnal IOP at weeks 2, 6, and 12.      
3. Safety and tolerability were primarily assessed by counts and clinical 
review of adverse events within 14 days after the last dose of treatment (or 
after discontinuation). The proportion of patients who reported 1 or more 
adverse events, a drug-related adverse event, or a serious adverse event; 
patients who discontinued because of an adverse event; and adverse events 
reported by at least 4 patients in any treatment group were calculated. The 
following groupings of adverse events were prespecified as being of 
special interest: conjunctival hyperemia, ocular pain/stinging/irritation, 































Baseline at All 9 
Time Points During 
the Study (0800, 
1000 and 1600 Hrs at 
Weeks 2, 6, and 12)   
  
  

































A combination of 
satisfactory or 
acceptable effect on 
IOP and a reduction 
of at least 20% of the 
total tolerance score 
on Day 84 in the 
worse eye 
Sum of scores of signs 
and symptoms, 
assessment of global 
discomfort and 
tolerance by the 
patient, assessment of 
both efficacy and 
tolerance by the 
patient, assessment of 
both the efficacy and 




comparison of the 
mean basal IOP after 
28 days of treatment. 
1. Baseline IOP, visual acuity.  
2. a combination of satisfactory or acceptable 
effect on IOP and a reduction of at least 20% 
of the total tolerance score on Day 28 in the 
worse eye.  
3. Comparison of the mean basal IOP at Day 
28 day and day 84 of treatment. 
4. Satisfactory or acceptable effect on IOP 
score. 
5. sum of scores of signs and symptoms. 
6. assessment of tolerance by the patient. 














[ Time Frame: Day 
84 ]: Response 
  
  























Source Primary outcome 
Other outcomes 
(from method section 
of Publication) 
Other outcomes (from results section of 
Publication) 
































defined as a 
combination of 
satisfactory or 
acceptable effect on 
IOP and a reduction 
of at least 20% of the 
total tolerance score 











hyperemia at week 
12 
corneal staining with 
fluorescein and TBUT. 
IOP measurements and 
adverse events. 
1. change from baseline in conjunctival 
hyperemia at 1 week.  
2. Mean corneal staining score at baseline, 12 
weeks. 3. Change from baseline in mean 
corneal staining score.  
4. Mean TBUT at baseline, 12 weeks.  
5. Change from baseline in mean TBUT.  
6. Percentage of patients with no change or 
a decrease 
in conjunctival hyperemia from baseline.  
7. Percentage of patient with a ≥1-unit 
increase in conjunctival hyperemia from 
baseline at week 12.  
8. Change from baseline at week 1, 4, and 12 
in mean IOP. 
9. AE 



















Mean Corneal Staining 
With Fluorescein at Week 
12; Mean Tear Break Up 
Time (TBUT) at Week 12; 
SAE and other AE 











hyperemia at month 
3. 




1. mean conjunctival hyperemia scores at 
baseline and at any follow-up visit. 
 2. change from baseline conjunctival 
hyperemia scores at week 1, month 1, and 
month 3.  
3. mean corneal staining at baseline and at any 
follow-up visit.  
4. change from baseline mean corneal staining 
at week 1, month 1, and month 3.  
5. mean TBUT at baseline and at any follow-
up visit. 6.change from baseline mean TBUT at 
week 1, month 1, and month 3.  
7.mean IOP at baseline and at any follow-up 
visit. 
 8. change from baseline mean IOP at week 1, 
month 1, and month 3. 
 9. SAE and AE 
  

































Source Primary outcome 
Other outcomes 
(from method section 
of Publication) 
Other outcomes (from results section of 
Publication) 




































Baseline in Mean 
Conjunctival 
Hyperemia Scores at 
Month 3     
1. Change From Baseline in 
Corneal Staining With 
Fluorescein at Month 3.     
2. Change From Baseline in 
Tear Break-Up Time 
(TBUT) at Month 3. 











diurnal IOP change 
from baseline at 
week 4 in the 
study eye. 
1. proportion of 
subjects with ≥ 
25%reduction in IOP 
from baseline to week 
4. 2. AE 
1. proportion of subjects with ≥ 25%reduction 
in IOP from baseline to week 4.  
2. Incidences of Adverse Event (AE) [ Time 
Frame: Up to 14 days after Week 4 visit ].  
3.  Incidences of Study Drug Discontinuation 
Due to an AE [ Time Frame: Up to Week 4]  





































Mean Diurnal IOP 
Change From 
Baseline at Week 4 - 
Study Eye   
  
  
1. Number of Participants 
With an Adverse Event 
(AE)   [ Time Frame: Up to 
14 days after Week 4 visit ].  
2. Number of Participants 
Who Discontinued Study 
Drug Due to an AE   [ Time 
Frame: Up to Week 4 ]. 
3. Number of Participants 
With ≥25% Reduction in 
IOP From Baseline to 
Week 4 - Study Eye. 
































1. ¶ See Appendix 2 for reference ID 
2. ROB: risk of bias 
3. IOP: intraocular pressure 
4. Color coding: 
M Misleading 
X Substantive difference across reports 
J Difference in completeness across reports, the journal article provides more information 
C Difference in completeness across reports, the ClinicalTrials.gov registration provides more information 
E Difference in completeness across reports, each provides some information 
  No difference across reports 
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ClinicalTrials.go
v: yes. FDA: no 

















































1 204251 c-09-038 NCT00961649   
 Placebo usage. 
ClinicalTrials.gov: reported. 
FDA: NR 
    
ClinicalTrials.gov: reported. 
FDA: NR 







































































mean IOP at each 
assessment time 
points (8 AM, + 2 
hrs, + 7 hrs, and + 9 
hrs) at Week 6 
AE and SAE; dropouts and/or 
Discontinuations; cardiovascular 
parameters (systolic blood 
pressure, diastolic blood 
pressure and heart rate) 




Mean Change in Intraocular Pressure 
(IOP) From Baseline to Each of the 
Assessment Time Points (8 AM, + 2 Hrs, 
+ 7 Hrs, and + 9 Hrs) at Week 6 














1. ROB: risk of bias 
2. IOP: intraocular pressure 
3. Color coding: 
M Misleading 
X Substantive difference across reports 
F Difference in completeness across reports, the FDA approval package provides more information 
C Difference in completeness across reports, the ClinicalTrials.gov registration provides more information 
E Difference in completeness across reports, each provides some information 







Table 9. Strengths and limitations of data sources 
Source Strengths Limitations 





• Include a large number of trials and 
participants 
• Provide detailed descriptions for 
interventions (e.g., dose, schedule) 
• Provide limited information about 
secondary outcomes and adverse 
events of trials 
Drugs
@FDA 
• Provide information about secondary 
outcomes and adverse events that may 
not be available elsewhere 
• Useful for identifying unpublished 
trials for regulated products 
• Only useful for products regulated by 
FDA 
• Approval packages prior to 1997 not 
readily available online  





• Useful for identifying unpublished 
trials on all types of interventions 
(including interventions not regulated 
by FDA)  
• Provide PICO in a tabulated format 
• Not all trials (and interventions 
evaluated in those trials) prior to 2000 
are available 
• Registration may be incomplete; not 
all results are available 
• Provide limited information about 
secondary outcomes and adverse 
events of trials 





• Provide most information about the 
trial design, statistical methods, and for 






• Provide limited information about the 
trial design; usually contain more 
information about missing data (and 
how they were handled; sometimes 





• Provide least information about the 
trial design, statistical methods; not 
useful for assessing risk of bias  
141 
 





• Almost always provide information 
about baseline characteristics 
• Provide reasonably complete 
information about result and precision 
measures 




• Provided results at all time points • Provided limited information about 
baseline characteristics or patient 
flow 





• Provide detailed information about 
patient flow  
• Provide limited information about 
baseline characteristics 
• Results may not be posted 





 • Substantial amount of time and 
resources needed for trial 




• Efficient for trial identification • Some obstacles for data extraction 
because of unstructured format for 





• Efficient for trial identification 
• Most efficient for data extraction when 





Table 10.1. Summary estimates of mean difference in IOP at 3 months derived from 































treatment Brimonidine 1 -2.30 -3.99 -0.61 NA NA -2.30 -4.50 -0.10 
 Betaxolol 3 -2.28 -3.65 -0.91 1.16 79% -2.24 -3.26 -1.23 
 Levobunolol 2 -7.51 -8.53 -6.50 0.00 0% -7.44 -8.92 -5.96 
 Timolol 5 -3.61 -4.63 -2.59 0.76 58% -3.58 -4.50 -2.67 
 Levobetaxolol 1 -3.00 -4.53 -1.47 NA NA -3.00 -5.08 -0.92 
 Brinzolamide 1 -2.28 -4.04 -0.52 NA NA -2.28 -4.54 -0.02 
 Dorzolamide 3 -1.33 -1.68 -0.98 0.00 0% -1.57 -2.74 -0.39 
 Bimatoprost 1 -4.60 -5.60 -3.60 NA NA -4.60 -6.31 -2.89 
 Unoprostone 1 -0.50 -1.70 0.70 NA NA -0.50 -2.34 1.34 
vs. 
Apraclonidin
e Timolol 2 -1.76 -3.27 -0.26 0.45 28% -1.76 -3.31 -0.21 
vs. 
Brimonidine Betaxolol 1 -0.04 -1.03 0.95 NA NA -0.04 -1.74 1.66 
 Timolol 4 -0.75 -2.15 0.66 1.72 94% -0.76 -1.58 0.06 
 Brinzolamide 4 -0.36 -1.43 0.71 0.97 84% -0.32 -1.14 0.50 
 Latanoprost 5 -1.08 -2.12 -0.05 1.13 83% -1.16 -1.92 -0.40 
 Travoprost 1 -1.20 -3.77 1.37 NA NA -1.20 -4.16 1.76 
vs. Betaxolol Levobunolol 2 -4.73 -10.01 0.55 12.25 83% -3.32 -5.17 -1.47 
 Timolol 8 -1.70 -2.41 -0.99 0.38 39% -1.71 -2.47 -0.95 
 Levobetaxolol 1 -2.00 -3.54 -0.46 NA NA -2.00 -4.08 0.08 






























 Latanoprost 2 -1.05 -2.62 0.51 0.33 25% -1.05 -2.73 0.63 
vs.Carteolol Levobunolol 1 -2.90 -4.59 -1.22 NA NA -2.90 -5.10 -0.70 
 Timolol 4 0.03 -0.61 0.68 0.11 24% 0.06 -0.85 0.97 
vs. 
Levobunolol Timolol 11 -0.03 -0.44 0.39 0.01 3% -0.01 -0.65 0.63 
vs. Timolol Levobetaxolol 3 1.25 0.27 2.23 0.52 73% 1.26 0.30 2.23 
 Brinzolamide 2 0.78 -1.04 2.61 1.00 41% 0.95 -0.48 2.38 
 Dorzolamide 6 1.20 0.52 1.88 0.39 56% 1.20 0.47 1.94 
 Bimatoprost 7 -2.09 -2.48 -1.71 0.05 19% -2.22 -2.87 -1.57 
 Latanoprost 14 -1.26 -1.68 -0.85 0.34 64% -1.28 -1.75 -0.81 
 Travoprost 7 -0.93 -1.30 -0.57 0.00 0% -0.93 -1.61 -0.24 
 Tafluprost 2 -0.93 -2.29 0.44 0.83 85% -0.88 -1.98 0.21 
 Unoprostone 3 1.43 0.39 2.47 0.72 86% 1.44 0.56 2.33 
vs. 
Brinzolamide Dorzolamide 2 0.32 -0.17 0.80 0.00 0% 0.30 -0.78 1.39 
 Travoprost 1 -2.70 -3.99 -1.41 NA NA -2.70 -4.60 -0.80 
vs. 
Dorzolamide Latanoprost 1 -2.90 -3.70 -2.10 NA NA -2.90 -4.49 -1.31 
vs. 
Bimatoprost Latanoprost 7 0.92 0.14 1.69 0.72 71% 0.90 0.21 1.59 
 Travoprost 10 0.53 -0.08 1.15 0.61 68% 0.53 -0.04 1.11 
vs. 
Latanoprost Travoprost 8 -0.11 -0.49 0.27 0.00 0% -0.10 -0.75 0.56 
 Tafluprost 1 -0.90 -3.40 1.60 NA NA -0.90 -3.80 2.00 
 Unoprostone 6 3.07 2.51 3.63 0.01 2% 2.95 2.12 3.78 
Legend: 
1. NA: Not applicable 
2. There are 110 two-arm trials, 10 three-arm trials, and 1 four-arm trial  
3. Mean difference is calucated using the IOP of the drug in column2-column1 
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4. Tau square: between-study variance in random-effect models; I square: proportion of variance due to heterogeneity 
5. Glaucoma drugs are expected to lower IOP; therefore, mean difference >0 favors the drug in column 1, and mean difference <0 favors the drug in 
column 2. 
6. *Estimated tau square is 0.4648; estimated I square is 64.17% 
7.Color coding: 
White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker 
Orange Carbonic anhydrase inhibitor 
































Table 10.2. Summary estimates of mean difference in IOP at 3 months derived from 




























treatment Brimonidine 1 -2.30 -3.99 -0.61 NA NA -2.30 -4.49 -0.11 
 Betaxolol 2 -2.90 -4.65 -1.15 1.30 81% -2.79 -4.00 -1.58 
 Levobunolol 2 -7.51 -8.53 -6.50 0.00 0% -7.44 -8.91 -5.97 
 Timolol 4 -3.90 -5.12 -2.69 0.85 56% -3.89 -4.95 -2.83 
 Brinzolamide 2 -1.75 -2.76 -0.75 0.00 0% -1.81 -3.24 -0.39 
 Dorzolamide 4 -1.38 -1.72 -1.04 0.00 0% -1.69 -2.68 -0.69 
 Bimatoprost 1 -4.60 -5.60 -3.60 NA NA -4.60 -6.30 -2.90 
 Unoprostone 1 -0.50 -1.70 0.70 NA NA -0.50 -2.33 1.33 
vs. 
Apraclonidine Timolol 2 -1.76 -3.27 -0.26 0.45 28% -1.76 -3.30 -0.22 
vs. 
Brimonidine Betaxolol 1 -0.04 -1.03 0.95 NA NA -0.04 -1.73 1.65 
 Timolol 4 -0.75 -2.15 0.66 1.72 94% -0.76 -1.57 0.06 
 Brinzolamide 2 0.00 -2.16 2.15 2.25 93% -0.01 -1.14 1.12 
 Latanoprost 5 -1.08 -2.12 -0.05 1.13 83% -1.16 -1.91 -0.40 
 Travoprost 1 -1.20 -3.77 1.37 NA NA -1.20 -4.14 1.74 
vs. Betaxolol Levobunolol 2 -4.73 -10.01 0.55 12.25 83% -3.32 -5.16 -1.48 
 Timolol 8 -1.54 -2.24 -0.83 0.43 50% -1.54 -2.27 -0.82 
 Dorzolamide 2 -0.30 -0.96 0.36 0.00 0% -0.35 -1.53 0.84 
 Latanoprost 2 -1.05 -2.62 0.51 0.33 25% -1.05 -2.72 0.63 



























vs. Carteolol Levobunolol 1 -2.90 -4.59 -1.22 NA NA -2.90 -5.09 -0.71 
 Timolol 4 0.03 -0.61 0.68 0.11 24% 0.06 -0.85 0.97 
vs. 
Levobunolol Timolol 11 -0.03 -0.44 0.39 0.01 3% -0.01 -0.64 0.63 
vs. Timolol Brinzolamide 3 1.19 0.59 1.79 0.00 0% 1.05 -0.06 2.15 
 Dorzolamide 5 0.91 0.29 1.54 0.23 46% 0.92 0.15 1.69 
 Bimatoprost 6 -1.98 -2.42 -1.55 0.06 21% -2.13 -2.85 -1.42 
 Latanoprost 13 -1.29 -1.76 -0.82 0.42 66% -1.30 -1.79 -0.81 
 Travoprost 4 -0.80 -1.36 -0.24 0.00 0% -0.72 -1.67 0.23 
 Tafluprost 2 -0.93 -2.29 0.44 0.83 85% -0.88 -1.98 0.21 
 Unoprostone 2 0.94 -0.43 2.31 0.85 87% 0.96 -0.12 2.05 
vs. 
Brinzolamide Dorzolamide 2 -0.20 -0.82 0.41 0.00 0% -0.24 -1.39 0.92 
vs. 
Dorzolamide Latanoprost 1 -2.90 -3.70 -2.10 NA NA -2.90 -4.49 -1.31 
vs. 
Bimatoprost Latanoprost 7 0.92 0.14 1.69 0.72 71% 0.90 0.22 1.59 
 Travoprost 9 0.59 -0.06 1.25 0.65 70% 0.60 -0.01 1.20 
vs. 
Latanoprost Travoprost 7 -0.04 -0.49 0.41 0.00 0% -0.06 -0.77 0.66 
 Tafluprost 1 -0.90 -3.40 1.60 NA NA -0.90 -3.78 1.98 
 Unoprostone 6 3.07 2.51 3.63 0.01 2% 2.95 2.13 3.78 
Legend: 
1. NA: Not applicable 
2. There are 95 two-arm trials,12 three-arm trials 
3. Mean difference is calucated using the IOP of the drug in column2-column1 
4. Tau square: between-study variance in random-effect models; I square: proportion of variance due to heterogeneity 




6. *Estimated tau square is 0.4729; estimated I square is 64.34% 
7.Color coding: 
White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker 
Orange Carbonic anhydrase inhibitor 

















Table 10.3. Summary estimates of mean difference in IOP at 3 months derived from 




























No treatment Betaxolol 1 -1.00 -2.19 0.20 NA NA -1.00 -2.42 0.42 
 Timolol 1 -2.70 -3.87 -1.53 NA NA -2.70 -4.09 -1.31 
 Levobetaxolol 1 -3.00 -4.53 -1.47 NA NA -3.00 -4.81 -1.19 
vs. Betaxolol Timolol 1 -1.70 -2.88 -0.52 NA NA -1.70 -3.11 -0.29 
 Levobetaxolol 1 -2.00 -3.54 -0.46 NA NA -2.00 -3.82 -0.18 
vs. Timolol Levobetaxolol 3 1.25 0.27 2.23 0.52 73% 1.49 0.92 2.05 
 Dorzolamide 4 1.61 0.93 2.29 0.06 12% 1.62 0.87 2.37 
 Bimatoprost 2 -2.26 -2.82 -1.70 0.00 0% -2.26 -2.93 -1.58 
 Latanoprost 1 -1.10 -1.69 -0.51 NA NA -1.10 -1.82 -0.38 
 Travoprost 3 -0.98 -1.45 -0.52 0.03 19% -0.98 -1.48 -0.48 
 Unoprostone 2 2.00 1.59 2.41 0.00 0% 2.00 1.50 2.50 
vs. Brinzolamide Dorzolamide 2 0.32 -0.17 0.80 NA NA 0.31 -0.27 0.90 
vs. Latanoprost Travoprost 1 -0.30 -1.03 0.43 NA NA -0.30 -1.18 0.58 
Legend: 
1. NA: Not applicable 
2. There are 14 two-arm trials,1 three-arm trial, and 1 four-arm trial 
3. Mean difference is calculated using the IOP of the drug in column2-column1 
4. Tau square: between-study variance in random-effect models; I square: proportion of variance due to heterogeneity 
5. Glaucoma drugs are expected to lower IOP; therefore, mean difference >0 favors the drug in column 1, and mean difference <0 favors the drug in 
column 2. 
6. *Estimated tau square is 0.0071; estimated I square is 29.99% 
7.Color coding: 
White Placebo/vehicle/no treatment 




Orange Carbonic anhydrase inhibitor 



















Table 10.4. Summary estimates of mean difference in IOP at 3 months derived from 

























vs. Brimonidine Brinzolamide 4 -1.09 -1.92 -0.26 0.51 73% -1.10 -2.03 -0.17 
vs. Timolol Travoprost 1 -1.80 -3.55 -0.05 NA NA -1.80 -4.19 0.59 
 Tafluprost 2 -0.75 -2.51 1.01 1.46 90% -0.70 -1.97 0.57 
vs. Brinzolamide Travoprost 1 -2.70 -3.99 -1.41 NA NA -2.70 -4.78 -0.62 
vs. Bimatoprost Travoprost 1 -0.14 -1.56 1.28 NA NA -0.14 -2.30 2.02 
Legend: 
1. NA: Not applicable 
2. There are 9 two-arm trials 
3. Mean difference is calucated using the IOP of the drug in column2-column1 
4. Tau square: between-study variance in random-effect models; I square: proportion of variance due to heterogeneity 
5. Glaucoma drugs are expected to lower IOP; therefore, mean difference >0 favors the drug in column 1, and mean difference <0 favors the drug in 
column 2. 
6. *Estimated tau square is 0.6926; estimated I square is 81.30% 
7.Color coding: 
White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker 
Orange Carbonic anhydrase inhibitor 







Table 10.5. Summary estimates of mean difference in IOP at 3 months derived from 



























/No treatment Brimonidine 1 -2.30 -3.99 -0.61 NA NA -2.30 -4.52 -0.08 
  Betaxolol 2 -2.90 -4.65 -1.15 1.30 81% -2.80 -4.04 -1.56 
  Levobunolol 2 -7.51 -8.53 -6.50 0.00 0% -7.44 -8.94 -5.94 
 Timolol 4 -3.90 -5.12 -2.69 0.85 56% -3.89 -4.97 -2.81 
 Brinzolamide 1 -2.28 -4.04 -0.52 NA NA -2.28 -4.56 0.00 
 Dorzolamide 3 -1.33 -1.68 -0.98 0.00 0% -1.58 -2.77 -0.38 
 Bimatoprost 1 -4.60 -5.60 -3.60 NA NA -4.60 -6.34 -2.86 
 Unoprostone 1 -0.50 -1.70 0.70 NA NA -0.50 -2.36 1.36 
vs. 
Apraclonidine Timolol 2 -1.76 -3.27 -0.26 0.45 28% -1.75 -3.32 -0.18 
vs. Brimonidine Betaxolol 1 -0.04 -1.03 0.95 NA NA -0.04 -1.77 1.69 
 Timolol 4 -0.75 -2.15 0.66 1.72 94% -0.76 -1.59 0.08 
 Latanoprost 5 -1.08 -2.12 -0.05 1.13 83% -1.15 -1.93 -0.38 
 Travoprost 1 -1.20 -3.77 1.37 NA NA -1.20 -4.17 1.77 
vs. Betaxolol Levobunolol 2 -4.73 -10.01 0.55 12.25 83% -3.34 -5.20 -1.47 
 Timolol 7 -1.73 -2.60 -0.85 0.60 48% -1.72 -2.56 -0.87 
 Dorzolamide 2 -0.30 -0.96 0.36 0.00 0% -0.35 -1.56 0.87 
 Latanoprost 2 -1.05 -2.62 0.51 0.33 25% -1.05 -2.75 0.65 
vs. Carteolol Levobunolol 1 -2.90 -4.59 -1.22 NA NA -2.90 -5.12 -0.68 
 Timolol 4 0.03 -0.61 0.68 0.11 24% 0.06 -0.87 0.99 
vs. Levobunolol Timolol 11 -0.03 -0.44 0.39 0.01 3% -0.01 -0.65 0.64 



























 Dorzolamide 2 0.65 -0.43 1.73 0.41 68% 0.65 -0.52 1.82 
 Bimatoprost 5 -2.08 -2.66 -1.50 0.15 36% -2.20 -3.01 -1.39 
 Latanoprost 13 -1.29 -1.76 -0.82 0.42 66% -1.30 -1.81 -0.80 
 Travoprost 3 -0.56 -1.39 0.27 0.00 0% -0.55 -1.77 0.66 
 Unoprostone 1 0.20 -0.63 1.03 NA NA 0.20 -1.44 1.84 
vs. Dorzolamide Latanoprost 1 -2.90 -3.70 -2.10 NA NA -2.90 -4.52 -1.28 
vs. Bimatoprost Latanoprost 7 0.92 0.14 1.69 0.72 71% 0.90 0.20 1.60 
 Travoprost 9 0.59 -0.06 1.25 0.65 70% 0.60 -0.02 1.21 
vs. Latanoprost Travoprost 7 -0.04 -0.49 0.41 0.00 0% -0.05 -0.79 0.68 
 Tafluprost 1 -0.90 -3.40 1.60 NA NA -0.90 -3.81 2.01 
 Unoprostone 6 3.07 2.51 3.63 0.01 2% 2.95 2.11 3.79 
Legend: 
1. NA: Not applicable 
2. There are 87 two-arm trials,9 three-arm trials 
3. Mean difference is calculated using the IOP of the drug in column2-column1 
4. Tau square: between-study variance in random-effect models; I square: proportion of variance due to heterogeneity 
5. Glaucoma drugs are expected to lower IOP; therefore, mean difference >0 favors the drug in column 1, and mean difference <0 favors the drug in 
column 2. 
6. *Estimated tau square is 0.4648; estimated I square is 64.17% 
7.Color coding: 
White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker 
Orange Carbonic anhydrase inhibitor 




































































trials 107 17343 14 95(89%) 12(11%) 0 36 9(25%) 11(31%) 2(1.75-5) 
Timolol 
(62,58%) 

















Table 12.1. Summary estimates of mean difference in IOP at 3 months derived from 
NMA (all unique trials) 
 
Legend:  
1. Glaucoma drugs are expected to lower IOP; therefore, mean difference <0 favors the drug in the column, and mean difference >0 favors the drug in 
the row. 
2. Color coding: 
White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 









Bimatoprost Travoprost Tafluprost Latanoprost Levobunolol Timolol Carteolol Brimonidine Brinzolamide Levobetaxolol Dorzolamide Betaxolol Apraclonidine Unoprostone Placebo
Bimatoprost 0.69 (0.19,1.19) 0.83 (-0.38,2.03) 0.88 (0.38,1.38) 1.05 (0.31,1.79) 1.87 (1.40,2.34) 2.14 (1.12,3.15) 2.60 (1.93,3.27) 2.68 (1.90,3.47) 3.06 (1.95,4.17) 3.27 (2.56,3.98) 3.32 (2.61,4.03) 3.59 (1.90,5.29) 3.73 (2.97,4.49) 5.60 (4.90,6.29)
-0.69 (-1.19,-0.19) Travoprost 0.13 (-1.07,1.33) 0.19 (-0.31,0.68) 0.36 (-0.39,1.11) 1.18 (0.70,1.66) 1.44 (0.43,2.46) 1.90 (1.24,2.57) 1.99 (1.22,2.76) 2.37 (1.26,3.48) 2.58 (1.87,3.29) 2.63 (1.91,3.35) 2.90 (1.20,4.59) 3.04 (2.28,3.80) 4.90 (4.19,5.61)
-0.83 (-2.03,0.38) -0.13 (-1.33,1.07) Tafluprost 0.05 (-1.10,1.21) 0.22 (-1.03,1.48) 1.04 (-0.07,2.16) 1.31 (-0.12,2.74) 1.77 (0.55,3.00) 1.86 (0.56,3.15) 2.24 (0.74,3.73) 2.44 (1.20,3.68) 2.50 (1.25,3.74) 2.77 (0.80,4.73) 2.91 (1.63,4.19) 4.77 (3.53,6.01)
-0.88 (-1.38,-0.38) -0.19 (-0.68,0.31) -0.05 (-1.21,1.10) Latanoprost 0.17 (-0.51,0.85) 0.99 (0.63,1.36) 1.26 (0.29,2.22) 1.72 (1.17,2.27) 1.80 (1.09,2.51) 2.18 (1.12,3.25) 2.39 (1.76,3.02) 2.44 (1.81,3.07) 2.71 (1.05,4.38) 2.85 (2.21,3.50) 4.72 (4.09,5.34)
-1.05 (-1.79,-0.31) -0.36 (-1.11,0.39) -0.22 (-1.48,1.03) -0.17 (-0.85,0.51) Levobunolol 0.82 (0.24,1.40) 1.09 (0.07,2.11) 1.55 (0.77,2.33) 1.63 (0.76,2.51) 2.01 (0.86,3.17) 2.22 (1.43,3.01) 2.27 (1.51,3.03) 2.54 (0.81,4.27) 2.68 (1.82,3.54) 4.54 (3.80,5.29)
-1.87 (-2.34,-1.40) -1.18 (-1.66,-0.70) -1.04 (-2.16,0.07) -0.99 (-1.36,-0.63) -0.82 (-1.40,-0.24) Timolol 0.27 (-0.63,1.16) 0.73 (0.19,1.26) 0.81 (0.14,1.48) 1.19 (0.19,2.20) 1.40 (0.84,1.96) 1.45 (0.89,2.02) 1.72 (0.10,3.35) 1.86 (1.22,2.51) 3.73 (3.17,4.28)
-2.14 (-3.15,-1.12) -1.44 (-2.46,-0.43) -1.31 (-2.74,0.12) -1.26 (-2.22,-0.29) -1.09 (-2.11,-0.07) -0.27 (-1.16,0.63) Carteolol 0.46 (-0.58,1.50) 0.55 (-0.57,1.67) 0.93 (-0.42,2.27) 1.13 (0.08,2.19) 1.19 (0.13,2.24) 1.46 (-0.40,3.31) 1.60 (0.49,2.70) 3.46 (2.41,4.51)
-2.60 (-3.27,-1.93) -1.90 (-2.57,-1.24) -1.77 (-3.00,-0.55) -1.72 (-2.27,-1.17) -1.55 (-2.33,-0.77) -0.73 (-1.26,-0.19) -0.46 (-1.50,0.58) Brimonidine 0.09 (-0.58,0.75) 0.46 (-0.67,1.59) 0.67 (-0.04,1.38) 0.73 (0.01,1.44) 1.00 (-0.72,2.71) 1.14 (0.34,1.93) 3.00 (2.28,3.71)
-2.68 (-3.47,-1.90) -1.99 (-2.76,-1.22) -1.86 (-3.15,-0.56) -1.80 (-2.51,-1.09) -1.63 (-2.51,-0.76) -0.81 (-1.48,-0.14) -0.55 (-1.67,0.57) -0.09 (-0.75,0.58) Brinzolamide 0.38 (-0.82,1.58) 0.59 (-0.16,1.33) 0.64 (-0.18,1.47) 0.91 (-0.85,2.67) 1.05 (0.15,1.96) 2.91 (2.11,3.71)
-3.06 (-4.17,-1.95) -2.37 (-3.48,-1.26) -2.24 (-3.73,-0.74) -2.18 (-3.25,-1.12) -2.01 (-3.17,-0.86) -1.19 (-2.20,-0.19) -0.93 (-2.27,0.42) -0.46 (-1.59,0.67) -0.38 (-1.58,0.82) Levobetaxolol 0.21 (-0.93,1.35) 0.26 (-0.86,1.38) 0.53 (-1.38,2.44) 0.67 (-0.52,1.86) 2.53 (1.42,3.65)
-3.27 (-3.98,-2.56) -2.58 (-3.29,-1.87) -2.44 (-3.68,-1.20) -2.39 (-3.02,-1.76) -2.22 (-3.01,-1.43) -1.40 (-1.96,-0.84) -1.13 (-2.19,-0.08) -0.67 (-1.38,0.04) -0.59 (-1.33,0.16) -0.21 (-1.35,0.93) Dorzolamide 0.05 (-0.65,0.75) 0.32 (-1.40,2.04) 0.46 (-0.36,1.29) 2.33 (1.64,3.01)
-3.32 (-4.03,-2.61) -2.63 (-3.35,-1.91) -2.50 (-3.74,-1.25) -2.44 (-3.07,-1.81) -2.27 (-3.03,-1.51) -1.45 (-2.02,-0.89) -1.19 (-2.24,-0.13) -0.73 (-1.44,-0.01) -0.64 (-1.47,0.18) -0.26 (-1.38,0.86) -0.05 (-0.75,0.65) Betaxolol 0.27 (-1.45,1.99) 0.41 (-0.42,1.24) 2.27 (1.60,2.95)
-3.59 (-5.29,-1.90) -2.90 (-4.59,-1.20) -2.77 (-4.73,-0.80) -2.71 (-4.38,-1.05) -2.54 (-4.27,-0.81) -1.72 (-3.35,-0.10) -1.46 (-3.31,0.40) -1.00 (-2.71,0.72) -0.91 (-2.67,0.85) -0.53 (-2.44,1.38) -0.32 (-2.04,1.40) -0.27 (-1.99,1.45) Apraclonidine 0.14 (-1.61,1.89) 2.00 (0.28,3.72)
-3.73 (-4.49,-2.97) -3.04 (-3.80,-2.28) -2.91 (-4.19,-1.63) -2.85 (-3.50,-2.21) -2.68 (-3.54,-1.82) -1.86 (-2.51,-1.22) -1.60 (-2.70,-0.49) -1.14 (-1.93,-0.34) -1.05 (-1.96,-0.15) -0.67 (-1.86,0.52) -0.46 (-1.29,0.36) -0.41 (-1.24,0.42) -0.14 (-1.89,1.61) Unoprostone 1.86 (1.06,2.66)
-5.60 (-6.29,-4.90) -4.90 (-5.61,-4.19) -4.77 (-6.01,-3.53) -4.72 (-5.34,-4.09) -4.54 (-5.29,-3.80) -3.73 (-4.28,-3.17) -3.46 (-4.51,-2.41) -3.00 (-3.71,-2.28) -2.91 (-3.71,-2.11) -2.53 (-3.65,-1.42) -2.33 (-3.01,-1.64) -2.27 (-2.95,-1.60) -2.00 (-3.72,-0.28) -1.86 (-2.66,-1.06) Placebo
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Table 12.2 Summary estimates of mean difference in IOP at 3 months derived from NMA 
(published trials) 
Legend:  
1. Glaucoma drugs are expected to lower IOP; therefore, mean difference <0 favors the drug in the column, and mean difference >0 favors the drug in 
the row. 
2. Color coding: 
White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 








Bimatoprost Travoprost Tafluprost Latanoprost Levobunolol Timolol Carteolol Brimonidine Brinzolamide Dorzolamide Betaxolol Apraclonidine Unoprostone Placebo
Bimatoprost 0.75 (0.18,1.31) 0.77 (-0.48,2.02) 0.82 (0.29,1.36) 0.98 (0.19,1.77) 1.83 (1.30,2.36) 2.09 (1.03,3.15) 2.46 (1.74,3.19) 2.95 (2.04,3.85) 3.08 (2.30,3.86) 3.09 (2.35,3.84) 3.54 (1.79,5.28) 3.62 (2.79,4.44) 5.52 (4.78,6.26)
-0.75 (-1.31,-0.18) Travoprost 0.02 (-1.26,1.30) 0.07 (-0.50,0.65) 0.23 (-0.60,1.06) 1.08 (0.49,1.66) 1.34 (0.25,2.44) 1.72 (0.96,2.48) 2.20 (1.26,3.14) 2.33 (1.51,3.15) 2.35 (1.56,3.13) 2.79 (1.02,4.55) 2.87 (2.01,3.73) 4.77 (3.98,5.57)
-0.77 (-2.02,0.48) -0.02 (-1.30,1.26) Tafluprost 0.05 (-1.14,1.25) 0.21 (-1.08,1.50) 1.06 (-0.09,2.21) 1.32 (-0.15,2.80) 1.69 (0.42,2.97) 2.18 (0.80,3.55) 2.31 (1.02,3.61) 2.32 (1.05,3.60) 2.77 (0.75,4.79) 2.85 (1.51,4.18) 4.75 (3.46,6.04)
-0.82 (-1.36,-0.29) -0.07 (-0.65,0.50) -0.05 (-1.25,1.14) Latanoprost 0.16 (-0.55,0.87) 1.01 (0.61,1.40) 1.27 (0.27,2.27) 1.64 (1.06,2.22) 2.12 (1.30,2.94) 2.26 (1.58,2.94) 2.27 (1.63,2.91) 2.71 (1.00,4.43) 2.79 (2.11,3.48) 4.70 (4.04,5.36)
-0.98 (-1.77,-0.19) -0.23 (-1.06,0.60) -0.21 (-1.50,1.08) -0.16 (-0.87,0.55) Levobunolol 0.85 (0.25,1.44) 1.11 (0.06,2.16) 1.48 (0.67,2.29) 1.97 (1.01,2.92) 2.10 (1.27,2.93) 2.11 (1.33,2.89) 2.56 (0.79,4.32) 2.63 (1.72,3.55) 4.54 (3.76,5.31)
-1.83 (-2.36,-1.30) -1.08 (-1.66,-0.49) -1.06 (-2.21,0.09) -1.01 (-1.40,-0.61) -0.85 (-1.44,-0.25) Timolol 0.27 (-0.66,1.19) 0.64 (0.07,1.21) 1.12 (0.35,1.89) 1.25 (0.64,1.87) 1.27 (0.70,1.84) 1.71 (0.04,3.37) 1.79 (1.08,2.50) 3.69 (3.10,4.28)
-2.09 (-3.15,-1.03) -1.34 (-2.44,-0.25) -1.32 (-2.80,0.15) -1.27 (-2.27,-0.27) -1.11 (-2.16,-0.06) -0.27 (-1.19,0.66) Carteolol 0.37 (-0.71,1.45) 0.85 (-0.34,2.05) 0.99 (-0.11,2.09) 1.00 (-0.08,2.08) 1.44 (-0.46,3.35) 1.52 (0.36,2.68) 3.43 (2.34,4.51)
-2.46 (-3.19,-1.74) -1.72 (-2.48,-0.96) -1.69 (-2.97,-0.42) -1.64 (-2.22,-1.06) -1.48 (-2.29,-0.67) -0.64 (-1.21,-0.07) -0.37 (-1.45,0.71) Brimonidine 0.48 (-0.34,1.30) 0.62 (-0.16,1.40) 0.63 (-0.11,1.37) 1.07 (-0.69,2.83) 1.15 (0.30,2.00) 3.05 (2.30,3.81)
-2.95 (-3.85,-2.04) -2.20 (-3.14,-1.26) -2.18 (-3.55,-0.80) -2.12 (-2.94,-1.30) -1.97 (-2.92,-1.01) -1.12 (-1.89,-0.35) -0.85 (-2.05,0.34) -0.48 (-1.30,0.34) Brinzolamide 0.13 (-0.72,0.99) 0.15 (-0.76,1.05) 0.59 (-1.24,2.42) 0.67 (-0.34,1.68) 2.57 (1.72,3.43)
-3.08 (-3.86,-2.30) -2.33 (-3.15,-1.51) -2.31 (-3.61,-1.02) -2.26 (-2.94,-1.58) -2.10 (-2.93,-1.27) -1.25 (-1.87,-0.64) -0.99 (-2.09,0.11) -0.62 (-1.40,0.16) -0.13 (-0.99,0.72) Dorzolamide 0.01 (-0.72,0.75) 0.46 (-1.32,2.23) 0.53 (-0.36,1.43) 2.44 (1.73,3.14)
-3.09 (-3.84,-2.35) -2.35 (-3.13,-1.56) -2.32 (-3.60,-1.05) -2.27 (-2.91,-1.63) -2.11 (-2.89,-1.33) -1.27 (-1.84,-0.70) -1.00 (-2.08,0.08) -0.63 (-1.37,0.11) -0.15 (-1.05,0.76) -0.01 (-0.75,0.72) Betaxolol 0.44 (-1.32,2.20) 0.52 (-0.31,1.36) 2.42 (1.72,3.13)
-3.54 (-5.28,-1.79) -2.79 (-4.55,-1.02) -2.77 (-4.79,-0.75) -2.71 (-4.43,-1.00) -2.56 (-4.32,-0.79) -1.71 (-3.37,-0.04) -1.44 (-3.35,0.46) -1.07 (-2.83,0.69) -0.59 (-2.42,1.24) -0.46 (-2.23,1.32) -0.44 (-2.20,1.32) Apraclonidine 0.08 (-1.73,1.89) 1.98 (0.21,3.75)
-3.62 (-4.44,-2.79) -2.87 (-3.73,-2.01) -2.85 (-4.18,-1.51) -2.79 (-3.48,-2.11) -2.63 (-3.55,-1.72) -1.79 (-2.50,-1.08) -1.52 (-2.68,-0.36) -1.15 (-2.00,-0.30) -0.67 (-1.68,0.34) -0.53 (-1.43,0.36) -0.52 (-1.36,0.31) -0.08 (-1.89,1.73) Unoprostone 1.90 (1.06,2.75)
-5.52 (-6.26,-4.78) -4.77 (-5.57,-3.98) -4.75 (-6.04,-3.46) -4.70 (-5.36,-4.04) -4.54 (-5.31,-3.76) -3.69 (-4.28,-3.10) -3.43 (-4.51,-2.34) -3.05 (-3.81,-2.30) -2.57 (-3.43,-1.72) -2.44 (-3.14,-1.73) -2.42 (-3.13,-1.72) -1.98 (-3.75,-0.21) -1.90 (-2.75,-1.06) Placebo
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Table 12.3. Summary estimates of mean difference in IOP at 3 months derived from 
NMA (FDA trials) 
 
Legend:  
1. Glaucoma drugs are expected to lower IOP; therefore, mean difference <0 favors the drug in the column, and mean difference >0 favors the drug in 
the row. 
2. Color coding: 
White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 







Bimatoprost Travoprost Latanoprost Timolol Brinzolamide Levobetaxolol Dorzolamide Unoprostone Betaxolol Placebo
Bimatoprost 1.28 (0.56,1.99) 1.30 (0.48,2.12) 2.26 (1.69,2.83) 3.57 (2.57,4.56) 3.75 (2.98,4.51) 3.88 (3.02,4.74) 4.26 (3.54,4.97) 4.48 (3.22,5.74) 5.48 (4.24,6.72)
-1.28 (-1.99,-0.56) Travoprost 0.02 (-0.61,0.66) 0.98 (0.55,1.41) 2.29 (1.37,3.20) 2.47 (1.81,3.13) 2.60 (1.83,3.37) 2.98 (2.38,3.59) 3.20 (2.00,4.40) 4.20 (3.02,5.39)
-1.30 (-2.12,-0.48) -0.02 (-0.66,0.61) Latanoprost 0.96 (0.38,1.54) 2.27 (1.27,3.26) 2.45 (1.66,3.24) 2.58 (1.71,3.45) 2.96 (2.23,3.69) 3.18 (1.92,4.44) 4.18 (2.94,5.42)
-2.26 (-2.83,-1.69) -0.98 (-1.41,-0.55) -0.96 (-1.54,-0.38) Timolol 1.31 (0.50,2.12) 1.49 (0.98,2.00) 1.62 (0.98,2.26) 2.00 (1.57,2.43) 2.22 (1.10,3.34) 3.22 (2.12,4.32)
-3.57 (-4.56,-2.57) -2.29 (-3.20,-1.37) -2.27 (-3.26,-1.27) -1.31 (-2.12,-0.50) Brinzolamide 0.18 (-0.77,1.14) 0.31 (-0.18,0.81) 0.69 (-0.22,1.61) 0.91 (-0.47,2.29) 1.91 (0.55,3.28)
-3.75 (-4.51,-2.98) -2.47 (-3.13,-1.81) -2.45 (-3.24,-1.66) -1.49 (-2.00,-0.98) -0.18 (-1.14,0.77) Levobetaxolol 0.13 (-0.68,0.94) 0.51 (-0.14,1.17) 0.73 (-0.45,1.91) 1.73 (0.56,2.90)
-3.88 (-4.74,-3.02) -2.60 (-3.37,-1.83) -2.58 (-3.45,-1.71) -1.62 (-2.26,-0.98) -0.31 (-0.81,0.18) -0.13 (-0.94,0.68) Dorzolamide 0.38 (-0.39,1.15) 0.60 (-0.69,1.89) 1.60 (0.32,2.88)
-4.26 (-4.97,-3.54) -2.98 (-3.59,-2.38) -2.96 (-3.69,-2.23) -2.00 (-2.43,-1.57) -0.69 (-1.61,0.22) -0.51 (-1.17,0.14) -0.38 (-1.15,0.39) Unoprostone 0.22 (-0.98,1.42) 1.22 (0.03,2.41)
-4.48 (-5.74,-3.22) -3.20 (-4.40,-2.00) -3.18 (-4.44,-1.92) -2.22 (-3.34,-1.10) -0.91 (-2.29,0.47) -0.73 (-1.91,0.45) -0.60 (-1.89,0.69) -0.22 (-1.42,0.98) Betaxolol 1.00 (-0.21,2.21)
-5.48 (-6.72,-4.24) -4.20 (-5.39,-3.02) -4.18 (-5.42,-2.94) -3.22 (-4.32,-2.12) -1.91 (-3.28,-0.55) -1.73 (-2.90,-0.56) -1.60 (-2.88,-0.32) -1.22 (-2.41,-0.03) -1.00 (-2.21,0.21) Placebo
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Table 12.4. Summary estimates of mean difference in IOP at 3 months derived from 
NMA (ClinicalTrials.gov trials) 
 
Legend:  
1. Glaucoma drugs are expected to lower IOP; therefore, mean difference <0 favors the drug in the column, and mean difference >0 favors the drug in 
the row. 
2. Color coding: 
White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 









Travoprost Bimatoprost Tafluprost Timolol Brinzolamide Brimonidine
Travoprost 0.14 (-2.02,2.30) 1.10 (-1.61,3.81) 1.80 (-0.59,4.19) 2.70 (0.62,4.78) 3.80 (1.52,6.08)
-0.14 (-2.30,2.02) Bimatoprost 0.96 (-2.51,4.43) 1.66 (-1.56,4.88) 2.56 (-0.44,5.56) 3.66 (0.52,6.80)
-1.10 (-3.81,1.61) -0.96 (-4.43,2.51) Tafluprost 0.70 (-0.58,1.98) 1.60 (-1.82,5.01) 2.70 (-0.85,6.24)
-1.80 (-4.19,0.59) -1.66 (-4.88,1.56) -0.70 (-1.98,0.58) Timolol 0.90 (-2.27,4.07) 2.00 (-1.30,5.30)
-2.70 (-4.78,-0.62) -2.56 (-5.56,0.44) -1.60 (-5.01,1.82) -0.90 (-4.07,2.27) Brinzolamide 1.10 (0.17,2.03)
-3.80 (-6.08,-1.52) -3.66 (-6.80,-0.52) -2.70 (-6.24,0.85) -2.00 (-5.30,1.30) -1.10 (-2.03,-0.17) Brimonidine
Glaucoma drugs are expected to lower IOP; therefore, mean difference <0 favors the drug in the column, and mean difference >0 favors the drug in the row.
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Table 12.5. Summary estimates of mean difference in IOP at 3 months derived from 
NMA (published trials not found on FDA or ClinicalTrials.gov) 
 
Legend:  
1. Glaucoma drugs are expected to lower IOP; therefore, mean difference <0 favors the drug in the column, and mean difference >0 favors the drug in 
the row. 
2. Color coding: 
White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 
Turquoise Prostaglandin analog 
 
 
Tafluprost Bimatoprost Travoprost Latanoprost Levobunolol Timolol Carteolol Brimonidine Brinzolamide Betaxolol
Tafluprost 0.09 (-2.99,3.17) 0.83 (-2.26,3.92) 0.90 (-2.13,3.93) 1.09 (-2.03,4.21) 1.92 (-1.14,4.98) 2.19 (-1.01,5.40) 2.46 (-0.64,5.55) 2.98 (-0.37,6.33) 3.25 (0.14,6.36)
-0.09 (-3.17,2.99) Bimatoprost 0.74 (0.13,1.34) 0.81 (0.23,1.39) 1.00 (0.15,1.84) 1.83 (1.24,2.42) 2.10 (0.98,3.23) 2.37 (1.56,3.17) 2.89 (1.39,4.38) 3.16 (2.32,3.99)
-0.83 (-3.92,2.26) -0.74 (-1.34,-0.13) Travoprost 0.07 (-0.56,0.70) 0.26 (-0.63,1.16) 1.09 (0.44,1.75) 1.37 (0.20,2.53) 1.63 (0.79,2.47) 2.15 (0.63,3.68) 2.42 (1.54,3.31)
-0.90 (-3.93,2.13) -0.81 (-1.39,-0.23) -0.07 (-0.70,0.56) Latanoprost 0.19 (-0.56,0.93) 1.02 (0.59,1.45) 1.29 (0.24,2.35) 1.56 (0.92,2.20) 2.08 (0.64,3.52) 2.35 (1.64,3.07)
-1.09 (-4.21,2.03) -1.00 (-1.84,-0.15) -0.26 (-1.16,0.63) -0.19 (-0.93,0.56) Levobunolol 0.83 (0.21,1.46) 1.10 (0.01,2.19) 1.37 (0.49,2.25) 1.89 (0.39,3.40) 2.16 (1.33,3.00)
-1.92 (-4.98,1.14) -1.83 (-2.42,-1.24) -1.09 (-1.75,-0.44) -1.02 (-1.45,-0.59) -0.83 (-1.46,-0.21) Timolol 0.27 (-0.69,1.23) 0.54 (-0.11,1.18) 1.06 (-0.33,2.45) 1.33 (0.68,1.98)
-2.19 (-5.40,1.01) -2.10 (-3.23,-0.98) -1.37 (-2.53,-0.20) -1.29 (-2.35,-0.24) -1.10 (-2.19,-0.01) -0.27 (-1.23,0.69) Carteolol 0.26 (-0.89,1.42) 0.79 (-0.90,2.47) 1.06 (-0.09,2.21)
-2.46 (-5.55,0.64) -2.37 (-3.17,-1.56) -1.63 (-2.47,-0.79) -1.56 (-2.20,-0.92) -1.37 (-2.25,-0.49) -0.54 (-1.18,0.11) -0.26 (-1.42,0.89) Brimonidine 0.52 (-0.99,2.04) 0.79 (-0.04,1.63)
-2.98 (-6.33,0.37) -2.89 (-4.38,-1.39) -2.15 (-3.68,-0.63) -2.08 (-3.52,-0.64) -1.89 (-3.40,-0.39) -1.06 (-2.45,0.33) -0.79 (-2.47,0.90) -0.52 (-2.04,0.99) Brinzolamide 0.27 (-1.24,1.77)
-3.25 (-6.36,-0.14) -3.16 (-3.99,-2.32) -2.42 (-3.31,-1.54) -2.35 (-3.07,-1.64) -2.16 (-3.00,-1.33) -1.33 (-1.98,-0.68) -1.06 (-2.21,0.09) -0.79 (-1.63,0.04) -0.27 (-1.77,1.24) Betaxolol
-3.32 (-6.47,-0.17) -3.23 (-4.20,-2.26) -2.49 (-3.50,-1.48) -2.42 (-3.28,-1.55) -2.23 (-3.23,-1.23) -1.40 (-2.22,-0.58) -1.13 (-2.38,0.13) -0.86 (-1.85,0.13) -0.34 (-1.92,1.24) -0.07 (-0.96,0.82)
-3.61 (-7.12,-0.10) -3.52 (-5.34,-1.69) -2.78 (-4.63,-0.94) -2.71 (-4.49,-0.93) -2.52 (-4.36,-0.69) -1.69 (-3.42,0.04) -1.42 (-3.39,0.56) -1.15 (-3.00,0.69) -0.63 (-2.84,1.58) -0.36 (-2.20,1.48)
-3.73 (-6.85,-0.60) -3.63 (-4.58,-2.69) -2.90 (-3.88,-1.91) -2.83 (-3.61,-2.04) -2.64 (-3.67,-1.61) -1.81 (-2.64,-0.97) -1.53 (-2.81,-0.26) -1.27 (-2.25,-0.28) -0.75 (-2.35,0.86) -0.48 (-1.49,0.54)
-5.73 (-8.84,-2.62) -5.63 (-6.44,-4.82) -4.90 (-5.77,-4.02) -4.83 (-5.54,-4.11) -4.64 (-5.46,-3.82) -3.80 (-4.45,-3.16) -3.53 (-4.68,-2.38) -3.27 (-4.11,-2.42) -2.74 (-4.19,-1.30) -2.47 (-3.25,-1.70)
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Green Difference in relative rankings compared to all-unique trial network  
White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 
Turquoise Prostaglandin analog  
 
 











Bimatoprost 99.3 99 100 79.1 95.8 1.1 1.1 1 2 1.6
Travoprost 86.8 83 83.6 85.1 81.3 2.8 3.2 2.5 1.7 3.4
Tafluprost 82.7 82.3 62 87.4 3.4 3.3 2.9 2.6
Latanoprost 81.3 81 83 79.8 3.6 3.5 2.5 3.6
Levobunolol 77.6 76.8 75.6 4.1 4 4.2
Timolol 62.2 59.4 66.7 39.1 59.1 6.3 6.3 4 4 6.3
Carteolol 56.6 52.8 51.8 7.1 7.1 7.3
Brimonidine 46.2 45.5 4.4 46.1 8.5 8.1 5.8 8
Brinzolamide 39.1 31.7 48.7 30.3 33.8 9.5 9.9 5.6 4.5 9.6
Levobetaxolol 33 42.2 10.4 6.2
Dorzolamide 26.1 27.1 34.8 24.7 11.4 10.5 6.9 10.8
Betaxolol 24.7 27.3 18.8 27 11.5 10.4 8.3 10.5
Apraclonidine 20.8 20.2 21.7 12.1 11.4 11.2
Unoprostone 13.4 13.8 21.1 15.9 13.1 12.2 8.1 11.9
Placebo 0.1 0.1 1 0.1 15 14 9.9 14
































Unique records identified 
n=10,936 
Duplicates excluded n=16,712 
Excluded by screening 
Not RCTs/not human study n=4,467 
Not medical intervention n=2,311 
Not POAG patients n=1,758 
Others n=485 
Excluded by full text review 
Not POAG patients, not first line 
medical interventions, no data for 
meta-analyses, other n=1811 
Insufficient data for meta-analysis n=8 
Trial reports included in the 
systematic review n=115 
 
Additional trial reports identified by 
matching ClinicalTrias.gov and Drugs@FDA 
records n=11 
Eligible trial reports n=104 
Trial reports included in 
meta-analysis n=107 
































Eligible trial reports n=27 
Trial reports included in the 
systematic review n=28 
 
Additional trial reports identified by 
matching ClinicalTrials.gov records n=1 
Excluded 
Not RCTs n=2 
Follow-up<28 days n=4 
Others n=42 
Drugs@FDA search n=72 
Insufficient data for meta-analysis 
n=12 





























Unique records identified 
n=511 
Duplicates excluded n=1 
Trial reports included in the 
systematic review n=27 
 
Excluded 
No results and no link to publication 
n=339 
Not RCT, follow-up< 28 days, not 
POAG patients, others n=147 
Eligible trial reports n=25 
Additional trial reports identified by 
matching Drugs@FDA records n=2 
Insufficient data for meta-analysis 
n=18 




Figure 2.1. The extent of overlap of trials among bibliographic 




1. n: Number of trials 
2. N: Number of participants 












Figure 2.2. The extent of overlap of trials among bibliographic 
database, Drugs@FDA, and ClinicalTrials.gov (trials with sufficient 
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Figure 3. Risk of bias assessment 
Trials from bibliographic databases  
 
 
Trials from Drugs@FDA 
 
 
Trials from ClinicalTrials.gov 
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Figure 4.1. Estimated mean difference in intraocular pressure at 3 months derived from 




White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 
Turquoise Prostaglandin analog 
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Figure 4.2. Estimated mean difference in intraocular pressure at 3 months derived from 




White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 
Turquoise Prostaglandin analog 
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White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 
Turquoise Prostaglandin analog 
Rank Placebo Unoprostone Apraclonidine Betaxolol Dorzolamide Levobetaxolol Brinzolamide Brimonidine Carteolol Timolol Levobunolol Latanoprost Tafluprost Travoprost Bimatoprost
Best 0 0 0 0 0 0 0 0 0 0 0.3 0 8.9 0.3 90.5
2nd 0 0 0 0 0 0 0 0 0.1 0 8.2 10.2 28 44 9.4
3rd 0 0 0 0 0 0 0 0 0 0 16 35 14.8 34 0.1
4th 0 0 0 0 0 0 0 0 0.5 0 27.9 39 16.6 15.9 0
5th 0 0 0.4 0 0 0 0.1 0 4.3 2.3 45.7 15.5 26 5.6 0
6th 0 0 1.5 0 0 0.9 0.4 0.3 23.6 67.1 1.8 0.2 4 0.1 0
7th 0 0 2.8 0.1 0.1 4.2 9.3 11.4 41.5 29.5 0.1 0 1.2 0 0
8th 0 0.1 5.3 1 0.9 11.9 27.4 37.4 14.7 1.1 0 0 0.3 0 0
9th 0 0.4 4.6 3 3.3 12.8 33.1 33.6 9 0 0 0 0.1 0 0
10th 0 2.1 8.6 13 16.9 22.6 19.7 13 4.1 0 0 0 0 0 0
11th 0 5.6 9.5 26.2 30.8 15.9 7.4 3.2 1.4 0 0 0 0 0 0
12th 0 12.6 9.3 32.3 28.7 13.7 1.9 0.9 0.6 0 0 0 0 0 0
13th 0 36.3 17 19.3 15.3 11.2 0.6 0.1 0.1 0 0 0 0 0 0
14th 1.1 42.9 39.9 5.1 4 6.8 0.1 0 0 0 0 0 0 0 0




















Best 2nd 3rd 4th 5th 6th 7th 8th
9th 10th 11th 12th 13th 14th Worst
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White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 
Turquoise Prostaglandin analog 
Rank Placebo Unoprostone Apraclonidine Betaxolol Dorzolamide Brinzolamide Brimonidine Carteolol Timolol Levobunolol Latanoprost Tafluprost Travoprost Bimatoprost
Best 0 0 0 0 0 0 0 0 0 0.6 0 11.3 0.4 87.7
2nd 0 0 0 0 0 0 0 0.1 0 11.6 15.6 29.9 30.8 12.1
3rd 0 0 0 0 0 0 0 0.3 0 18.3 36.6 13.8 30.7 0.2
4th 0 0 0 0 0 0 0 0.6 0 26.5 33.5 15.8 23.5 0
5th 0 0 0.3 0 0 0 0.1 4.1 2.8 41.2 14.1 23.3 14.2 0
6th 0 0 1.5 0 0 0.2 1.2 23.5 67.2 1.7 0.3 4.1 0.3 0
7th 0 0 3.1 0.6 0.6 3 21.3 40.8 29 0.1 0 1.5 0 0
8th 0 0.3 7.3 3.9 4.1 11.2 52.9 19.2 1 0 0 0.2 0 0
9th 0 1.7 8.9 18.1 15.9 29.7 18.7 6.8 0 0 0 0.1 0 0
10th 0 4.7 7.9 27.4 29 23.6 4.4 2.9 0 0 0 0 0 0
11th 0 9.8 8.7 31 30.6 17.4 1.3 1.2 0 0 0 0 0 0
12th 0 37.1 18.6 15.9 16.1 11.6 0.2 0.5 0 0 0 0 0 0
13th 1.3 46.3 42.4 3.1 3.6 3.3 0 0 0 0 0 0 0 0




















Best 2nd 3rd 4th 5th 6th 7th
8th 9th 10th 11th 12th 13th Worst
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White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 
Turquoise Prostaglandin analog 
Rank Placebo Betaxolol Unoprostone Dorzolamide Levobetaxolol Brinzolamide Timolol Latanoprost Travoprost Bimatoprost
Best 0 0 0 0 0 0 0 0.1 0 99.9
2nd 0 0 0 0 0 0 0 47.2 52.7 0.1
3rd 0 0 0 0 0 0 0.2 52.5 47.3 0
4th 0 0 0 0 0 0.1 99.7 0.2 0 0
5th 0 4.7 0.7 3.7 31.1 59.7 0.1 0 0 0
6th 0.1 6.7 5.1 35.1 28 25 0 0 0 0
7th 0.2 8.2 10.9 38.1 32.2 10.4 0 0 0 0
8th 1 18.4 51.9 17.3 7.6 3.8 0 0 0 0
9th 5.6 56.9 29.9 5.5 1.1 1 0 0 0 0

























Best 2nd 3rd 4th 5th 6th 7th 8th 9th
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White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 




Rank Brimonidine Brinzolamide Timolol  Tafluprost Bimatoprost Travoprost
Best 0 0.3 0.7 15.6 41 42.3
2nd 0.1 2.1 6.3 16.1 31.3 44.1
3rd 0.5 15.2 18.1 43 13 10.2
4th 6.1 14.3 48.3 15.7 12.3 3.3
5th 7.7 67.5 16 7.3 1.6 0
Worst 85.6 0.6 10.7 2.3 0.7 0
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White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 
Turquoise Prostaglandin analog 
Rank Placebo Unoprostone Apraclonidine Dorzolamide Betaxolol Brinzolamide Brimonidine Carteolol Timolol Levobunolol Latanoprost Travoprost Bimatoprost Tafluprost
Best 0 0 0 0 0 0 0 0 0 0.5 0 0.3 46.2 52.9
2nd 0 0 0 0 0 0 0 0.1 0 6.4 7.8 17.7 52.7 15.4
3rd 0 0 0 0 0 0.1 0 0.3 0 18.9 37.1 37.9 1 4.8
4th 0 0 0.1 0 0 0.3 0 0.8 0.1 26.1 39.8 27.4 0.1 5.3
5th 0 0 0.5 0 0 1.2 0.5 5.1 7.1 45.4 14.9 15.9 0 9.3
6th 0 0 1.7 0.1 0 5.1 5.2 22.9 58 2.4 0.4 0.7 0 3.4
7th 0 0.1 2.7 0.7 0.3 7.8 22.8 31.1 31.1 0.2 0 0 0 3.2
8th 0 0.5 6.5 3.2 2.8 14 43.9 23.3 3.4 0 0 0 0 2.3
9th 0 3.2 10.4 12.8 16.6 23.1 21.4 11 0.3 0 0 0 0 1.3
10th 0 9.1 12 23.1 31.6 15.1 5 3.6 0 0 0 0 0 0.5
11th 0 16.2 11 28.2 29.4 12.3 0.9 1.2 0 0 0 0 0 0.8
12th 0 32.1 16.6 22.6 15.4 11.9 0.3 0.6 0 0 0 0 0 0.6
13th 1.1 38.9 37.3 9.2 3.9 9.1 0 0 0 0 0 0 0 0.4
Worst 98.9 0 1.1 0 0 0 0 0 0 0 0 0 0 0
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Figure 8. Estimated mean difference in intraocular pressure at 3 months derived from 




White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 




Appendix 1. Search strategies 
 
ClinicalTrials.gov* 
Glaucoma AND (Bimatoprost OR Xalatan OR Travoprost OR Tafluprost OR 
Unoprostone OR Dorzolamide OR Cosopt OR Brinzolamide OR Timolol OR 
Levobunolol OR Carteolol OR Betaxolol OR Brimonidine OR Alphagan OR 
Apraclonidine OR Dipivefrin OR Pilocarpine) 
 
Glaucoma AND (Levobetaxolol OR Echothiophate OR Demecarium OR Metipranolol) 
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Appendix 3. Inconsistency analysis 
 
Because the number of drugs included in different networks are different, we used the 







trial FDA trial CT.gov trial 
Placebo/Vehicle/No treatment 1 1 1 Not included 
Apraclonidine 2 2 Not included Not included 
Brimonidine 3 3 Not included 1 
Betaxolol 4 4 2 Not included 
Carteolol 5 5 Not included Not included 
Levobunolol 6 6 Not included Not included 
Timolol 7 7 3 2 
Levobetaxolol 8 Not included 4 Not included 
Brinzolamide 9 8 5 3 
Dorzolamide 10 9 6 Not included 
Bimatoprost 11 10 7 4 
Latanoprost 12 11 8 Not included 
Travoprost 13 12 9 5 
Tafluprost 14 13 Not included 6 
Unoprostone 15 14 10 Not included 
 
1. Loop-specific approach 
We used loop-specific approach to estimate an inconsistency factor (IF) for each closed 
loop in all-unique trial and published trial network. The IF is the difference between 
direct and indirect estimates. The following inconsistency plots (Appendix 3 figure 1 and 
2) present all triangular and quadratic loops in the network and the respective IF and their 
95% CIs. Statistically significant inconsistency is present when the lower CI of IF does 
not reach the zero line.  
 
We detected evidence of statistical inconsistency in the three triangular loops of the all 
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2. Modeling inconsistency 
We applied design-by-treatment interaction inconsistency models to check for overall 
inconsistency in each network. We found inconsistency at the overall level in the all-
unique trial and the published trial networks (Appendix 3 table 1). 
 
We compared the inconsistency model and consistency model using both AIC (Akaike 
Information Criterion) and BIC (Bayesian Information Criterion) for model fit. 
Inconsistency models did not improve the model fit (Appendix 3 table 2).  
 
3. Side-split approach (Node-split approach) 
We used side-specific approach to estimate local inconsistency in the all-unique trial and 
published trial networks. The following tables (Appendix 3 table 3 and 4) report the 
estimated direct and indirect effects and their differences. The p-value is a test of 
consistency. Evidence of statistical inconsistency was found in two sides of the all-unique 



















Appendix 3 Table 1 Modeling inconsistency testing results 
Network Chi-square P value 
All-unique trial 64.05 0.0038 































freedom AIC BIC 
All-unique 
trial Consistency 121 -773.2598 15 1576.52 1618.456 
 Inconsistency 121 -709.0076 52 1522.015 1667.396 
Published 
trial Consistency 107 -678.8472 14 1385.694 1423.114 
 Inconsistency 107 -615.5491 50 1331.098 1464.74 












Appendix 3 Table 3. Side-split estimates (All-unique trial 
network) 
Side 
Direct Indirect Difference 
Coefficient SE Coefficient SE Coefficient SE P value 
01 03 -2.3 1.164134 -3.075347 0.3848194 0.7753472 1.226089 0.527 
01 04 -2.254772 0.5559589 -2.28498 0.4439738 0.030208 0.7113948 0.966 
01 06 -7.443528 0.7374297 -3.647608 0.401637 -3.79592 0.8400829 <0.001 
01 07 -3.598537 0.4920707 -3.791175 0.3516375 0.192638 0.6044004 0.75 
01 08 -2.690202 1.098351 -2.484202 0.6557017 -0.2059997 1.256402 0.87 
01 09 -2.28 1.193074 -2.999094 0.4372812 0.7190939 1.270685 0.571 
01 10 -1.597396 0.6407625 -2.626286 0.4127301 1.02889 0.7619672 0.177 
01 11 -4.6 0.9320135 -5.760193 0.380059 1.160194 1.006526 0.249 
01 15 -0.5 0.9882314 -2.137627 0.4466699 1.637627 1.084488 0.131 
02 07* -1.721988 0.8297689 -5.728755 141.4392 4.006767 141.4443 0.977 
03 04 -0.0400334 0.931284 0.8651027 0.3969729 -0.9051361 1.012362 0.371 
03 07 -0.758611 0.4602837 -0.7088643 0.3413367 -0.0497467 0.5725672 0.931 
03 09 -0.3335984 0.4512047 0.6319677 0.5150939 -0.9655661 0.6847503 0.159 
03 12 -1.13607 0.4117077 -2.201031 0.3744871 1.064961 0.5566703 0.056 
03 13 -1.166894 1.51934 -1.941603 0.3482496 0.7747084 1.558254 0.619 
04 06 -3.698475 0.9731842 -1.998906 0.4255329 -1.699569 1.062228 0.11 
04 07 -1.746724 0.4076599 -1.159246 0.4073257 -0.5874778 0.575915 0.308 
04 08 -1.943592 1.089464 0.311068 0.6455598 -2.25466 1.245588 0.07 
04 10 -0.3469696 0.6533139 0.073912 0.4302213 -0.4208817 0.7822207 0.591 
04 12 -1.045531 0.8808725 -2.655783 0.3442204 1.610252 0.9457974 0.089 
05 06 -2.900099 1.155004 -0.6291871 0.5778235 -2.270912 1.29148 0.079 
05 07 0.0631267 0.4910633 -2.208853 1.194386 2.27198 1.291373 0.079 
06 07 -0.0163721 0.3173688 3.324773 0.5555049 -3.341145 0.639411 <0.001 
07 08* 1.230483 0.5341989 0.7671107 1.548627 0.4633721 1.601289 0.772 
07 09 0.8906295 0.7879835 0.7926974 0.3834832 0.0979322 0.8763087 0.911 
07 10 1.20672 0.3992229 1.603108 0.4100332 -0.396388 0.5726677 0.489 
07 11 -2.234394 0.357049 -1.564081 0.3267921 -0.6703128 0.4842143 0.166 
07 12 -1.295281 0.2585126 -0.6589983 0.2696237 -0.636283 0.3741619 0.089 
07 13 -0.9242972 0.3739428 -1.366098 0.324499 0.4418007 0.4948384 0.372 
07 14 -0.9042284 0.6118585 -1.902382 1.509619 0.9981535 1.628926 0.54 
07 15 1.43334 0.4914406 2.210808 0.4408102 -0.777468 0.6600149 0.239 
09 10 0.3023935 0.6081101 0.7725025 0.4888086 -0.470109 0.7802174 0.547 
09 13 -2.700056 1.023329 -1.86359 0.4282679 -0.8364654 1.109331 0.451 
10 12 -2.900017 0.8840274 -2.312537 0.3437054 -0.5874803 0.9484925 0.536 
11 12 0.9380867 0.3754434 0.8297019 0.3478069 0.1083848 0.51177 0.832 
11 13 0.5237479 0.3143546 1.025894 0.4400789 -0.5021462 0.5408405 0.353 
12 13 -0.053102 0.3558085 -0.3253227 0.3634745 0.2722206 0.5082481 0.592 




Direct Indirect Difference 
Coefficient SE Coefficient SE Coefficient SE P value 
12 15 2.930625 0.4469339 2.763982 0.4859581 0.1666432 0.6604505 0.801 




Appendix 3 Table 4. Side-split estimates (Published trial 
network) 
Side 
Direct Indirect Difference 
Coefficient SE Coefficient SE Coefficient SE P value 
01 03 -2.3 1.187698 -3.144127 0.4074083 0.8441271 1.255631 0.501 
01 04 -2.83293 0.6912884 -2.269799 0.4261333 -0.5631303 0.8120134 0.488 
01 06 -7.440595 0.7491729 -3.601976 0.4155754 -3.838619 0.8571359 <0.001 
01 07 -3.898235 0.5799344 -3.615408 0.3537606 -0.2828269 0.6791653 0.677 
01 08 -1.809676 0.7810297 -2.925899 0.5312848 1.116223 0.9481578 0.239 
01 09 -1.74374 0.5561203 -2.921061 0.4659918 1.177321 0.7253378 0.105 
01 10 -4.6 0.9620217 -5.686724 0.4111015 1.086724 1.046179 0.299 
01 14 -0.5 1.013886 -2.209539 0.4751332 1.709539 1.119695 0.127 
02 07* -1.709156 0.8496725 -5.67356 141.4329 3.964405 141.4383 0.978 
03 04 -0.0400347 0.9619458 0.7537764 0.4123756 -0.7938111 1.046611 0.448 
03 07 -0.7570194 0.4771192 -0.5629909 0.3712428 -0.1940285 0.6040083 0.748 
03 08 -0.0077284 0.6455272 0.8347285 0.5469576 -0.8424569 0.846095 0.319 
03 11 -1.127472 0.425508 -2.117483 0.4078233 0.9900111 0.5893447 0.093 
03 12 -1.167744 1.537659 -1.753204 0.4012957 0.5854604 1.589331 0.713 
04 06 -3.736638 0.9917545 -1.800841 0.433524 -1.935798 1.082356 0.074 
04 07 -1.604731 0.4060524 -0.9020261 0.421495 -0.7027048 0.5856782 0.23 
04 09 -0.3400322 0.674211 0.1354042 0.4540594 -0.4754365 0.8134583 0.559 
04 11 -1.043914 0.8971274 -2.457442 0.3493604 1.413527 0.9628229 0.142 
04 14 0.5956492 0.8629164 0.4967152 0.4958862 0.098934 0.9958656 0.921 
05 06 -2.900098 1.177628 -0.6541258 0.5935108 -2.245972 1.318738 0.089 
05 07 0.0649214 0.5048714 -2.18216 1.218171 2.247081 1.318626 0.088 
06 07 -0.0161534 0.3214898 3.420803 0.5624286 -3.436957 0.6474484 <0.001 
07 08 1.007501 0.6273221 1.193592 0.5116339 -0.1860917 0.8144236 0.819 
07 09 0.9133038 0.435028 1.617772 0.4495557 -0.7044678 0.6273492 0.261 
07 10 -2.160663 0.4045025 -1.559041 0.3631966 -0.6016216 0.5439324 0.269 
07 11 -1.321821 0.2807638 -0.6619546 0.2926311 -0.6598662 0.4063371 0.104 
07 12 -0.7041169 0.5317212 -1.253253 0.3617995 0.549136 0.6434583 0.393 
07 13 -0.9106708 0.6342926 -1.919237 1.529757 1.008566 1.656074 0.543 
07 14 0.949807 0.6177459 2.211388 0.4386942 -1.261581 0.7587647 0.096 
08 09 -0.2512428 0.6607027 0.4374613 0.5847181 -0.6887041 0.8834773 0.436 
09 11 -2.900018 0.9135118 -2.150094 0.3766852 -0.7499236 0.9881273 0.448 
10 11 0.9389158 0.386214 0.7030374 0.3922596 0.2358784 0.550511 0.668 
10 12 0.5875317 0.3388964 1.171842 0.5499201 -0.5843108 0.6457836 0.366 
11 12 -0.0057505 0.4006879 -0.1568373 0.4392003 0.1510868 0.5943251 0.799 
11 13 -0.900343 1.516195 0.10995 0.666295 -1.010293 1.65613 0.542 
11 14 2.923878 0.4574624 2.605287 0.5499054 0.3185911 0.7157209 0.656 




Appendix 4. Sensitivity analysis 
 
For sensitivity analysis, we re-analyzed the all-unique trial network after removing 3 trials that 
are outliers and that may have resulted in heterogeneity and inconsistency. The effect estimates 

























Appendix 4 Table 1. Summary estimates of mean difference in IOP at 3 months derived 
from NMA (all-unique trial network sensitivity analysis) 
 
Legend:  
1. Glaucoma drugs are expected to lower IOP; therefore, mean difference <0 favors the drug in the column, and mean difference >0 favors the drug in 
the row. 
2. Color coding: 
White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 
Turquoise Prostaglandin analog 
 
Bimatoprost Travoprost Tafluprost Latanoprost Levobunolol Timolol Carteolol Brimonidine Brinzolamide Levobetaxolol Dorzolamide Betaxolol Apraclonidine Unoprostone Placebo
-0.70 (-1.20,-0.19) Travoprost 0.14 (-1.06,1.34) 0.18 (-0.32,0.68) 0.41 (-0.36,1.18) 1.19 (0.71,1.67) 1.46 (0.44,2.48) 1.90 (1.24,2.57) 1.98 (1.21,2.76) 2.37 (1.26,3.48) 2.57 (1.86,3.28) 2.66 (1.92,3.39) 2.91 (1.21,4.61) 3.03 (2.27,3.80) 4.84 (4.12,5.55)
-0.83 (-2.04,0.37) -0.14 (-1.34,1.06) Tafluprost 0.04 (-1.12,1.19) 0.27 (-1.00,1.54) 1.05 (-0.06,2.16) 1.32 (-0.11,2.75) 1.76 (0.53,2.99) 1.84 (0.55,3.14) 2.23 (0.73,3.73) 2.43 (1.19,3.67) 2.52 (1.26,3.77) 2.77 (0.80,4.74) 2.89 (1.62,4.17) 4.70 (3.45,5.95)
-0.87 (-1.37,-0.37) -0.18 (-0.68,0.32) -0.04 (-1.19,1.12) Latanoprost 0.23 (-0.48,0.94) 1.01 (0.64,1.38) 1.28 (0.31,2.25) 1.72 (1.17,2.27) 1.81 (1.09,2.52) 2.19 (1.13,3.26) 2.39 (1.76,3.02) 2.48 (1.82,3.13) 2.73 (1.06,4.40) 2.86 (2.21,3.50) 4.66 (4.01,5.30)
-1.10 (-1.87,-0.34) -0.41 (-1.18,0.36) -0.27 (-1.54,1.00) -0.23 (-0.94,0.48) Levobunolol 0.78 (0.17,1.39) 1.05 (0.02,2.08) 1.49 (0.70,2.29) 1.58 (0.68,2.47) 1.96 (0.80,3.13) 2.16 (1.36,2.97) 2.25 (1.46,3.03) 2.50 (0.76,4.24) 2.63 (1.75,3.51) 4.43 (3.66,5.19)
-1.88 (-2.36,-1.41) -1.19 (-1.67,-0.71) -1.05 (-2.16,0.06) -1.01 (-1.38,-0.64) -0.78 (-1.39,-0.17) Timolol 0.27 (-0.63,1.17) 0.71 (0.18,1.25) 0.80 (0.12,1.47) 1.18 (0.18,2.19) 1.38 (0.82,1.94) 1.47 (0.89,2.05) 1.72 (0.09,3.35) 1.85 (1.20,2.49) 3.65 (3.08,4.22)
-2.15 (-3.17,-1.14) -1.46 (-2.48,-0.44) -1.32 (-2.75,0.11) -1.28 (-2.25,-0.31) -1.05 (-2.08,-0.02) -0.27 (-1.17,0.63) Carteolol 0.44 (-0.60,1.49) 0.52 (-0.60,1.64) 0.91 (-0.44,2.26) 1.11 (0.06,2.17) 1.20 (0.13,2.26) 1.45 (-0.41,3.31) 1.57 (0.47,2.68) 3.38 (2.32,4.43)
-2.60 (-3.27,-1.93) -1.90 (-2.57,-1.24) -1.76 (-2.99,-0.53) -1.72 (-2.27,-1.17) -1.49 (-2.29,-0.70) -0.71 (-1.25,-0.18) -0.44 (-1.49,0.60) Brimonidine 0.08 (-0.59,0.75) 0.47 (-0.66,1.60) 0.67 (-0.04,1.38) 0.75 (0.03,1.48) 1.01 (-0.70,2.72) 1.13 (0.34,1.93) 2.93 (2.21,3.66)
-2.68 (-3.47,-1.89) -1.98 (-2.76,-1.21) -1.84 (-3.14,-0.55) -1.81 (-2.52,-1.09) -1.58 (-2.47,-0.68) -0.80 (-1.47,-0.12) -0.52 (-1.64,0.60) -0.08 (-0.75,0.59) Brinzolamide 0.39 (-0.81,1.59) 0.59 (-0.16,1.33) 0.67 (-0.16,1.51) 0.93 (-0.84,2.69) 1.05 (0.15,1.96) 2.85 (2.04,3.66)
-3.07 (-4.18,-1.96) -2.37 (-3.48,-1.26) -2.23 (-3.73,-0.73) -2.19 (-3.26,-1.13) -1.96 (-3.13,-0.80) -1.18 (-2.19,-0.18) -0.91 (-2.26,0.44) -0.47 (-1.60,0.66) -0.39 (-1.59,0.81) Levobetaxolol 0.20 (-0.94,1.34) 0.28 (-0.84,1.41) 0.54 (-1.38,2.45) 0.66 (-0.53,1.85) 2.46 (1.34,3.59)
-3.27 (-3.98,-2.56) -2.57 (-3.28,-1.86) -2.43 (-3.67,-1.19) -2.39 (-3.02,-1.76) -2.16 (-2.97,-1.36) -1.38 (-1.94,-0.82) -1.11 (-2.17,-0.06) -0.67 (-1.38,0.04) -0.59 (-1.33,0.16) -0.20 (-1.34,0.94) Dorzolamide 0.08 (-0.63,0.79) 0.34 (-1.38,2.06) 0.46 (-0.37,1.29) 2.26 (1.57,2.96)
-3.35 (-4.08,-2.62) -2.66 (-3.39,-1.92) -2.52 (-3.77,-1.26) -2.48 (-3.13,-1.82) -2.25 (-3.03,-1.46) -1.47 (-2.05,-0.89) -1.20 (-2.26,-0.13) -0.75 (-1.48,-0.03) -0.67 (-1.51,0.16) -0.28 (-1.41,0.84) -0.08 (-0.79,0.63) Betaxolol 0.25 (-1.47,1.98) 0.38 (-0.47,1.22) 2.18 (1.49,2.87)
-3.60 (-5.30,-1.91) -2.91 (-4.61,-1.21) -2.77 (-4.74,-0.80) -2.73 (-4.40,-1.06) -2.50 (-4.24,-0.76) -1.72 (-3.35,-0.09) -1.45 (-3.31,0.41) -1.01 (-2.72,0.70) -0.93 (-2.69,0.84) -0.54 (-2.45,1.38) -0.34 (-2.06,1.38) -0.25 (-1.98,1.47) Apraclonidine 0.13 (-1.63,1.88) 1.93 (0.20,3.65)
-3.73 (-4.49,-2.97) -3.03 (-3.80,-2.27) -2.89 (-4.17,-1.62) -2.86 (-3.50,-2.21) -2.63 (-3.51,-1.75) -1.85 (-2.49,-1.20) -1.57 (-2.68,-0.47) -1.13 (-1.93,-0.34) -1.05 (-1.96,-0.15) -0.66 (-1.85,0.53) -0.46 (-1.29,0.37) -0.38 (-1.22,0.47) -0.13 (-1.88,1.63) Unoprostone 1.80 (0.99,2.61)
-5.53 (-6.23,-4.83) -4.84 (-5.55,-4.12) -4.70 (-5.95,-3.45) -4.66 (-5.30,-4.01) -4.43 (-5.19,-3.66) -3.65 (-4.22,-3.08) -3.38 (-4.43,-2.32) -2.93 (-3.66,-2.21) -2.85 (-3.66,-2.04) -2.46 (-3.59,-1.34) -2.26 (-2.96,-1.57) -2.18 (-2.87,-1.49) -1.93 (-3.65,-0.20) -1.80 (-2.61,-0.99) Placebo
203 
 
Appendix 4 Table 2. SUCRA values and mean ranks generated by 
NMA (all-unique trial network sensitivity analysis) 
Drugs SUCRA value Mean rank 
Bimatoprost 99.3 1.1 
Travoprost 87.2 2.8 
Tafluprost 82.9 3.4 
Latanoprost 81.8 3.5 
Levobunolol 76.5 4.3 
Timolol 62.2 6.3 
Carteolol 55.4 7.2 
Brimonidine 46 8.6 
Brinzolamide 43.3 8.9 
Levobetaxolol 31.9 10.5 
Dorzolamide 25.3 11.5 
Betaxolol 23.3 11.7 
Apraclonidine 20.9 12.1 
Unoprostone 13.9 13.1 
Placebo 0.1 15 
Legend: 
Color coding: 
White Placebo/vehicle/no treatment 
Purple Alpha-2 adrenergic agonist 
Yellow Beta-blocker  
Orange Carbonic anhydrase inhibitor 
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